WO2015181837A2 - Novel compounds as anti-tubercular agents - Google Patents

Novel compounds as anti-tubercular agents Download PDF

Info

Publication number
WO2015181837A2
WO2015181837A2 PCT/IN2015/000226 IN2015000226W WO2015181837A2 WO 2015181837 A2 WO2015181837 A2 WO 2015181837A2 IN 2015000226 W IN2015000226 W IN 2015000226W WO 2015181837 A2 WO2015181837 A2 WO 2015181837A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
alkyl
methylpiperidin
piperidin
diphenylacetate
Prior art date
Application number
PCT/IN2015/000226
Other languages
French (fr)
Other versions
WO2015181837A3 (en
Inventor
Sundeep Dugar
Dinesh MAHAJAN
Santosh Kumar Rai
Kanury RAO
Varshneya SINGH
Original Assignee
Sphaera Pharma Pvt. Ltd.
Drug Discovery Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphaera Pharma Pvt. Ltd., Drug Discovery Research Centre filed Critical Sphaera Pharma Pvt. Ltd.
Priority to EP15800492.9A priority Critical patent/EP3148518B1/en
Priority to US15/313,986 priority patent/US10100012B2/en
Priority to CN201580041254.0A priority patent/CN106659697B/en
Priority to RU2016152499A priority patent/RU2016152499A/en
Priority to BR112016028081A priority patent/BR112016028081A2/en
Priority to JP2017515286A priority patent/JP6836502B2/en
Publication of WO2015181837A2 publication Critical patent/WO2015181837A2/en
Publication of WO2015181837A3 publication Critical patent/WO2015181837A3/en
Priority to US15/674,033 priority patent/US10207993B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine

Definitions

  • the present invention relates to novel compounds useful as anti-tubercular agents. More particularly, the present invention relates to substituted derivatives, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of tuberculosis.
  • Tuberculosis causes nearly two million deaths annually. Recent years have witnessed a resurgence of efforts directed at tuberculosis (TB) drug research and development. An analysis of the chronology of anti-tuberculosis therapy suggests a renewed interest in tuberculosis research.
  • MDR-TB Multidrug resistance TB
  • XDR-TB extensively drug resistance TB
  • TDR-TB totally drug resistance TB
  • India has the world's one of the highest burden of tuberculosis, wherein MDR tuberculosis accounts for nearly 5,000,000s cases annually which have been increased by more than 6% in the past 10 years.
  • M. tuberculosis develops resistance to drugs by induced or spontaneous mutation of its genome. It is also hypothesized that in case of certain drugs the bacterial cell wall, does not permit adequate permeability, thereby resulting in inadequate/minor amount of drug entering the bacteria. Such amount is insufficient to kill the bacteria, but the presence of minor amount, induces the bacteria to become resistant to the same. It is also hypothesized that M. tuberculosis acquires resistance by modification of its enzyme by unknown mechanisms. Traditional antitubercular drugs administered via oral route, act by inhibiting the synthesis of mycolic acid and/or by inhibiting the mycobacterial arabinosyltransferase, an essential component of mycobacterial cell wall.
  • G-protein coupled receptors such as GPR109A also plays an important role in tuberculosis.
  • GPR109A receptor is located on the cell surface and inhibits adenylyl cyclase along with consequent suppression of P A-signaling resulting in reduced triglyceride turnover which is further responsible for accumulation of lipid body inside the cell. Increase in the concentration of lipid body inside the cell favors the growth of M. tuberculosis and prevents respiratory burst.
  • a GPR109A inhibitor prevents the formation of lipid body by creating a hostile environment for the tuberculosis and thus induces respiratory burst.
  • Host macrophages infected by M. tuberculosis acquire foamy phenotype characterized by the intracellular accumulation of lipid bodies induced by pathogen through modulation of lipolysis of neutral lipids. This dysregulation influences the lipolysis by modulating the cAMP dependent signaling pathway.
  • M. tuberculosis Current resistant tuberculosis treatment, has greater risk of side effects and lasts for 18-24 months and target processes or enzymes within M. tuberculosis but suffers from the risk of generating newer variants exhibiting drug resistance. Since, M. tuberculosis survives within the human macrophage through modulation of a range of host cellular processes hence, a pharmacological target within the host that has been co-opted by M. tuberculosis for its survival should be a breakthrough approach for therapy. Additionally such an approach should be insensitive to whether the infecting strain was drug sensitive or drug resistant and preclude the development of resistance.
  • An object of the invention is to provide compounds useful as anti -tubercular agents.
  • the present invention provides novel ula 1 :
  • X is selected from O, NH or N(alkyl);
  • Ri and R 2 are independently selected from hydrogen, deuterium, hydroxyl, Cj-io straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci. 6 alkoxy, aryl, amino, NH(alkyl), N(alkyl) 2 OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group comprising O, N or S; or Ri and R 2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group comprising O, N or S;
  • R 3 isselected from hydrogen, hydroxyl, Ci -6 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci ⁇ alkoxy, aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic rings elected from:
  • X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, O or S.
  • the heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH- aralkyl;-
  • R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium,
  • R5 is hydrogen, hydroxy, Cl-6alkyl, Cl-6alkoxy, amino, NH(alkyl), N(alkyl)2;
  • R6 and R7 are independently selected from the group comprising hydrogen, CI -10 alkyl, -
  • R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl
  • n 1 ,2, or 3. and salts, hydrates and stereoisomers thereof.
  • Figure 1 depicts the effects of the compounds of the present invention in MYC-431 infected THP-1 macrophages
  • Figure 2 depicts the effects of the compounds of the present invention on Lipid Bodies
  • Figure 3 depicts the potency of compound 1085 of the present invention in Cellular M.tb
  • Figure 4 represents the effect of compound 1085 on adenylyl cyclase (c-AMP) in THP-1 macrophages
  • Figure 5a and 5b represents the Co-localization of M. tuberculosis with degradative vesicles: acidified lysosomes and autophagosomes in the presence of compound 1085
  • Figure 6 represents the effect of compound 1085 on cellular lipid body
  • Figure 7 represents the effect of compound 1085 on various mycobacterial strains
  • Figure 8 represents the effect of compound 1085 on the mycobacterial growth alone and in combination with other pharmaceutical agents
  • Figure 9a and 9b represents the pharmacokinetic parameters of compound 1085 administered via intraperitoneal route
  • Figure 10 represents the combination treatment of compound 1085 with Antituberculer therapy (ATT) DETAILED DESCRIPTION OF THE INVENTION
  • ATT Antituberculer therapy
  • the present invention provides novel compound of Formula 1 as antitubercular agents.
  • the present invention relates to novel compounds of Formula (1 ):
  • X is selected from O or NH
  • R) and R 2 are independently selected from hydrogen, deuterium, hydroxyl, CMO straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci -6 alkoxy, aryl, amino, NH(alkyl), N(alkyl) 2j OCOR 5 , heteroaryl containing 1 -3 heteroatoms selected from the group comprising O, N or S; or Ri and R 2 may combined to form an aryl or a heteroaryl ring containing 1 -3 heteroatoms selected from the group comprising 0, N or S;
  • R 3 is selected from hydrogen, hydroxyl, Ci- 6 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci -6 alkoxy, aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
  • X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, 0 or S.
  • the heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH- aralkyl;
  • R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium,
  • R5 is hydrogen, hydroxy, Cl-6alkyl, Cl-6alkoxy, amino, NH(alkyl), N(alkyl)2;
  • R6 and R7 are independently selected from the group comprising hydrogen, CI -10 alkyl, -
  • R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl
  • n 1 ,2, or 3;
  • X is NH
  • Ri and R 2 are selected from hydrogen, hydroxyl, C MO alkyl, C 1-6 alkoxy;
  • R3 is selected from substituted aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected fro
  • R4 is selected from hydrogen, deuterium, halogen, Ci -6 straight chain or branched chain alkyl, Ci -6 alkoxy, amino, NH(alkyl), N(alkyl) 2 ;
  • R 6 and R 7 are independently selected from hydrogen, Ci -10 alkyl, -COR 8 , -CH 2 OCOR 8 , - CH 2 OCONHR 8 R 9 , -COOR 8 , -CONR 8 R 9 , -S0 2 R 8 , phenyl, benzyl;
  • R 8 and R 9 are independently selected from hydrogen or C 1-6 straight chain or branched chain alkyl
  • n 1 ,2 or 3.
  • alkyl refers to a linear or branched saturated monovalent hydrocarbon, wherein the alkylene may optionally be substituted as described herein.
  • alkyl also encompasses both linear and branched alkyl, unless otherwise specified.
  • the alkyl is a linear saturated monovalent hydrocarbon that has the specified number of carbon atoms, or branched saturated monovalent hydrocarbon of specified number of carbon atoms.
  • linear CI- C6 and branched C3- C6 alkyl groups are also referred as "lower alkyl.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl (including allisomeric forms), n-propyl, isopropyl, butyl (including all isomeric forms), rc-butyl, isobutyl, sec-butyl, t-buly ⁇ , pentyl (including all isomeric forms), and hexyl (including all isomeric forms).
  • CI - C6 alkyl refers to a linear saturated monovalent hydrocarbon of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon of 3 to 6 carbon atoms.
  • aryl refers to a monocyclic aromatic group and/or multicyclic monovalent aromatic group that contain at least one aromatic hydrocarbon ring. In certain embodiments, the aryl has from 6 to 20 (C6 - C20), from 6 to 15 (C6 - CI 5), or from 6 to 10 (C6 - CIO) ring atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl.
  • Aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). In certain embodiments, aryl may be optionally substituted as described herein.
  • alkoxy refers to the group R'0 ⁇ wherein R' is alkyl.
  • the term “lower alkoxy” refers to alkoxy groups having from 1 to 3 carbon atoms; examples include methoxy, ethoxy, isopropoxy, and the like.
  • cycloalkyl refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. Cycloalkyl can include any number of carbons, such as C 3-6 , C 4- 6, C 5-6 , C 3-8 , C 4-8 , C 5-8 , and C 6 8 . Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl.
  • Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2]bicyclooctane, decahydronaphthalene and adamantane. Cycloalkyl groups can also be partially unsaturated, having one or more double bonds in the ring.
  • cycloalkyl groups that are partially unsaturated include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1 ,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4- and 1 ,5-isomers), norbornene, and norbornadiene. Unless otherwise stated, cycloalkyl groups are unsubstituted. A "substituted cycloalkyl" group can be substituted with one or more moieties selected from halo, hydroxy, amino, alkylamino, nitro, cyano, and alkoxy.
  • aralkyl or "aryl-alkyl” refers to a monovalent alkyl group substituted with aryl. Incertain embodiments, the alkyl and aryl moieties are optionally substituted as described herein.
  • heteroaryl refers to a monocyclic aromatic group and/or multicyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms independently selected from 0, S, and N.
  • Each ring of a heteroaryl group may contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms.
  • monocyclic heteroaryl groups include, but are not limited to, furanyl,imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl,pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl,and triazolyl.
  • bicyclic heteroaryl groups include, but are not limited to,benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl
  • tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl.
  • heteroaryl may also be optionally substituted as described herein.
  • heteroaralkyl refers to an aralkyl group as defined above, in which one or more (preferably 1 , 2, 3 or 4) carbon atoms have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulphur atom (preferably oxygen, sulphur or nitrogen), that is to say groups that in accordance with the above definitions contain both aryl or heteroaryl and alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups.
  • a hetero-aralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) with from 5 or 6 to 10 carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups having from 1 or 2 to 6 carbon atoms and/or a cycloalkyl group having 5 or 6 ring carbon atoms, with 1 , 2, 3 or 4 of those carbon atoms having been replaced by oxygen, sulphur or nitrogen atoms.
  • Examples are aryl-heteroalkyl, aryl-heterocycloalkyl, aryl- heterocycloalkenyl, arylalkyl-heterocycloalkyl, arylalkenyl-heterocycloalkyl, arylalkynyl- heterocycloalkyl, arylalkyl-heterocycloalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroaryl-heteroalkyl, heteroarylcyclo-alkyl, heteroarylcycloalkenyl, heteroaryl-heterocycloalkyl, heteroaryl-heterocycloalkenyl, heteroarylalkylcycloalkyl, _ g _ heteroarylalkyl-heterocycloalkenyl, heteroaryl-heteroalkyl-cycloalkyl, heteroaryl- heteroalkylcycloalkenyl and hetero
  • heterocyclyl refers to a monocyclic non-aromatic ring system and/or multicyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from 0, S, or N; and the remaining ring atoms are carbon atoms.
  • the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms.
  • the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused or bridged ring system, and in which thenitrogen or sulfur atoms may be optionally oxidized, the nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic.
  • the heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in thecreation of a stable compound.
  • heterocyclic compounds include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, p-carbolinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl
  • halogen refers to fluorine, chlorine, bromine, and iodine.
  • heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur, phosphorus and selenium.
  • aromatic as used herein, refers to an unsatured cyclic moiety that has an aromatic character. The term is intended to encompass both hydrocarbon aromatic compounds and heteroaromatic compounds.
  • hydrocarbon aromatic ring or “hydrocarbon aromatic compound” refer to an aromatic ring or compound in which the aromatic moieties have only carbon and hydrogen atoms.
  • heteromatic ring or “heteroaromatic compound' refer to an aromatic ring or compound wherein in at least one aromatic moiety one or more of the carbon atoms within the cyclic group has been replaced by another atom, such as nitrogen, oxygen, sulfur, or the like.
  • non-aromatic refers to a cyclic moiety, that may be unsaturated, but that does not have an aromatic character.
  • substituted refers to where hydrogen radical on a molecule has been replaced by another atom radical, a functional group radical or a moiety radical; these radicals being generally referred to as "substituents.”
  • a group such as an alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, dialkylamino, carboxamido, cycloalkyl, cycloalkylene, aryl, arylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene, may be substituted with one or more substituents independently selected from,e.g., (a) CI - C6 alkyl, C2 - C6 alkenyl, C2 - C6 alkynyl, C3 - C7 cycloalkyl, C6 - C14 aryl, C7 - C15aralkyl, heteroaryl, and heterocyclyl, each optionally substituted with one or more substituents; and (b) halo, cyano (-CN), nitro (-N02),-C(O)R3
  • salt(s) denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. Zwitterions (internal or inner salts) are included within the term “salt(s)” as used herein (and may be formed, for example, where the R substituents comprise a basic moiety such as an amino group). Also included herein are quaternary ammonium salts such as alkyl ammonium salts. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred.
  • pharmaceutically acceptable salts refers to the acid addition salt compound formed with a suitable acid selected from an inorganic acid such as hydrochloric acid, hydrobromic acid; or an organic acid such as benzene sulfonic acid, maleic acid, oxalic acid, fumaric acid, succinic acid, p-toluenesulfonic acid and malic acid.
  • a suitable acid selected from an inorganic acid such as hydrochloric acid, hydrobromic acid; or an organic acid such as benzene sulfonic acid, maleic acid, oxalic acid, fumaric acid, succinic acid, p-toluenesulfonic acid and malic acid.
  • hydrate designates a crystalline molecular compound in which water molecules are incorporated into the crystal lattice. Generally speaking, a hydrate thus designates a crystalline form of a molecular compound, whereby the only further molecules incorporated into the crystal lattice are water molecules.
  • stereoisomer' s refers to at least two compounds having the same molecular formula and connectivity of atoms, but having a different arrangement of atoms in a three- dimensional space.
  • a stereoisomer can be, for example, an enantiomer, a diastereomer, or a meso compound.
  • prophylactic refers variously to medicaments, amounts or quantities, methods, uses and effects, etc., that prevent and/or aid in preventing infections.
  • terapéutica refers to preventing, ameliorating, treating, improving, or curing a disease or condition.
  • DAS Directly Observed Treatment Short-Course
  • a four-drug such as Rifampicin, Isoniazid, Ethambutol and Pyrazinamide
  • Rifampicin and Isoniazid two-drug
  • MDR-TB Multidrug resistance Tuberculosis
  • IH isoniazid
  • RMP rifampicin
  • XDR-TB Extensively drug resistance Tuberculosis
  • XDR-TB refers to the tuberculosis which are resistant to atleast three of the six classes of second line antituberculosis drugs as well as isoniazid and rifampicin, plus any fluoroquinolone and at least one of three injectable second-line drugs such asamikacin, kanamycin, or capreomycin.
  • TDR-TB totally Drug Resistance Tuberculosis
  • first and second line drugs tested such as isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, ciprofloxacin, capreomycin, kanamycin.
  • H37Rv refers to a pathogenic M. tuberculosis strain that has been sequenced.
  • JAL2287 refers to the MDR (multi drug resistant) strainof M tuberculosis
  • MYC431 refers to the XDR (extensive drug resistant) strain of M. tuberculosis
  • GPR109A refers to the G-protein coupled receptor GPR109A.
  • the present invention provides compound represented by formula (1) that inhibits mycobacterium colony growth alone or in combination with DOTS (Directly Observed Treatment Short Course) therapy.
  • DOTS Directly Observed Treatment Short Course
  • the present invention also provides for compounds of formula (1) as below: i. 1 -methylpiperidin-3-yl-2-hydroxy-2,2-diphenylacetate; ii. 3-(2-hydroxy-2,2-diphenylacetoxy)-l-(((isopropylcarbamoyl)oxy)methyl)-l- methylpiperidin- 1 -ium; iii. piperidin-3-yl 2-hydroxy-2,2-diphenylacetate; iv. l-benzylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate; v. 1 -(methylsulfonyl)piperidin-3-yl 2-hydroxy-2,2-diphenylacetate; vi.
  • the present invention includes within its scope the salts and isomers.
  • Compounds of the present invention after being novel may in some cases form salts which are also within the scope of this invention.
  • All stereoisomer' s of the present compounds, such as those which may exist due to asymmetric carbons on the R substituents of the compound, including enantiomeric and diastereomeric forms, are contemplated within the scope of this invention.
  • the present invention may also optionally envisage within its scope the effect of selection of suitable counter ions.
  • the present invention includes in its scope, the modification of deuterated compounds.
  • Deuterated compounds are those wherein the compounds have selective incorporation of deuterium in place of hydrogen.
  • the Compounds of the present invention may be present in their enantiomeric pure forms or their mixtures.
  • the compounds of the present invention may be synthesized by the any of the synthetic schemes as shown below:
  • the compounds of present invention may be synthesized by coupling A with B in the presence of (i) as depicted in the scheme above.
  • X is selected from O, NH or N(alkyl);
  • Ri and R 2 are independently selected from hydrogen, deuterium, hydroxyl, C O straight chain or branched chain alkyl, 3-7 membered cycloalkyl, C] -6 alkoxy, aryl, amino, NH(alkyl), N(alkyl) 2 OCOR 5 , heteroaryl containing 1-3 heteroatoms selected from the group comprising O, N or S; or Ri and R 2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group comprising O, N or S; R 3 isselected from hydrogen, hydroxyl, Ci -6 straight chain or branched chain alkyl, 3-7 membered aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
  • X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, O or S.
  • the heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH- aralkyl;
  • R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, CI -6 alkoxy, amino, NH(alkyl), N(alkyl)2, -COOR8, CONR8R9;
  • R5 is hydrogen, hydroxy, Cl -6alkyl, Cl-6alkoxy, amino, NH(alkyl), N(alkyl)2;
  • R6 and R7 are independently selected from the group comprising hydrogen, CI -10 alkyl, - COR8, -CH20COR8, -CH20CONHR8R9, -COOR8, -CONR8R9, -S02R8, aryl, aralkyl;
  • R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl; n is 1 ,2, or 3. and salts, hydrates and stereoisomers thereof.
  • a general procedure involves the coupling reactions of acid with an amine or alcohol (R 3 X).
  • an acid (A) is used as a starting material which can be activated by converting it to corresponding acid chloride using reagent such thionyl chloride or oxalyl chloride in a solvent such as DCM with or without a small amount of DMF at temperature ranging from room temperature to reflux and then by reaction of this acid chloride with a desired amine or alcohol (R 3 X)to arrive at other members of the series.
  • an acid coupling reagent is such as carbodiimide in an organic solvent such as DMF with or without an organic base such DMAP.
  • acid can be activated by converting to corresponding ester using alcohol such as methanol first before reacting it with an amine or alcohol in a solvent such as benzene with or without a base such as sodium methoxide to arrive at other members of the series.
  • the invention thus provides the use of the novel compounds as defined herein for use in human or veterinary medicine.
  • the compounds of the present invention may be used in the treatment and prevention of diseases caused by mycobacteria such as tuberculosis.
  • the said tuberculosis may be caused by mycobacterial species consisting of Mycobacterium tuberculosis, M. bovis, M africanum, M. canettior M. microti.
  • the compounds of the present invention are effective in inhibiting the growth of the M. tuberculosis.
  • Tuberculosis as mentioned herein comprises active tuberculosis or latent tuberculosis.
  • the active tuberculosis comprises drug sensitive, mono-drug resistant, multi-drug-resistant tuberculosis (MDR), extensively drug- resistant tuberculosis (XDR) or totally drug resistant tuberculosis.
  • the compounds of the present invention may be used in the treatment of tuberculosis including MDR, XDR and TDR tuberculosis.
  • the compounds of the present invention may be used either alone or in combination with cycloserine, amikacin, linezolid, ethambutol, rifampicin, isoniazid, ethionamide, moxyfloxacin, clarithromycin, PAS, clofazamine, streptomycin, capreomycin and kanamycin and DOTS ("Directly Observed Treatment, Short-course") therapy.
  • the compounds of the present invention may also be used prophylactically in preventing the occurrence of tuberculosis in healthcare providers, health workers, community members and the alike who are directly in contact with tuberculosis patients.
  • the compounds of the present invention may be used for treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis as defined above.
  • the compounds of the present invention are effective against tuberculosis and said tuberculosis includes drug- sensitive, mono-drug resistance, multi drug-resistant (MDR), extensively drug-resistance (XDR) and totally drug resistance (TDR) caused by a strain of Mycobacterium tuberculosis Mycobacterium strains.
  • MDR multi drug-resistant
  • XDR extensively drug-resistance
  • TDR totally drug resistance
  • the compounds of the present invention may be used for the treatment of multi-drug-resistant (MDR), extensively drug-resistance (XDR) and totally drug resistance (TDR) tuberculosis caused by a strain Mycobacterium tuberculosis and for treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis as defined above by inhibition of GPR109A inhibition by an agent.
  • MDR multi-drug-resistant
  • XDR extensively drug-resistance
  • TDR totally drug resistance
  • the compound for use as a pharmaceutical may be presented as a pharmaceutical composition.
  • the invention therefore provides in a further aspect a pharmaceutical composition comprising the novel compounds of the invention along with pharmaceutically acceptable excipients/carriers thereof and optionally other therapeutic and/or prophylactic ingredients.
  • the excipients/carriers must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
  • the pharmaceutical composition will be in an appropriate formulation.
  • the pharmaceutical formulations may be any formulation and include those suitable for oral, intranasal, or parenteral (including intramuscular and intravenous) administration.
  • the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
  • the compounds of the present invention may be administered orally, topically, intranasally, , parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasteral injection or infusion techniques.
  • warm-blooded animals such as mice, rats, horses, dogs, cats, etc.
  • the compounds of the present invention are effective in the treatment of humans.
  • compound of the present invention may be administered in a dose ranging from 0.1 to 100 mg/kg body weight per day.
  • the compounds of the present invention are useful for the prevention and treatment of tuberculosis and may be used as GPR109A inhibitors.
  • Step 1
  • Step 3 [1064] was synthesized similar to [1065] as described in step 2.
  • Analytical Data [1064] was synthesized similar to [1065] as described in step 2.
  • Example 1 Inhibition of mycobacterium colony growth in macrophage by compounds of the present invention.
  • THP1 cells were seeded in a tissue culture plate in complete RPMI + 10% FCS and were allowed to differentiate to macrophages by addition of PMA with incubation at 37°C with 5% CO2. After 16-20 hr of PMA differentiation, cells were washed and replenished with complete RPMI. PMA-differentiated THP-1 cell were infected with tuberculosis bacteria H37Rv at an MOI of 10. Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged prior to incubation at 37°C with 5% C0 2 .
  • Example 3 In vitro infection of human PBMC derived macrophages, compound addition and cfu determination.
  • Heparinised human blood diluted 1 : 1 with RPMI 1640 was layered onto equal volume of Ficoll-Paque followed by centrifugation at 1600 rpm for 30 min.
  • the PBMC layer formed at the interface was collected carefully and washed twice with RPMI.
  • the cells were diluted in RMPI medium (without serum) to a concentration 2 x l0 6 /ml and 10 ml of diluted cells were put into a 75-cm 2 tissue culture flask, and incubated for 2 hrs in a humidified 37°C incubator.
  • the non-adherent cells were removed by aspiration, followed by two washes with RPMI.
  • Human PBMC derived macrophages were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5% C0 2 . After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200 ⁇ g/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment.
  • Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i.
  • the cells were lysed in 50 ⁇ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 ⁇ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently flow in parallel tracks along the agar surface.
  • Example 4 In vitro infection of THP-1 macrophages, compound addition and cfu determination.
  • the human monocyte/ macrophage cell line THP-1 was cultured in RPMI 1640 supplemented with 10% FCS and were maintained between 2 and 10 X 105 cells per ml at 37°C in a humidified, 5% C0 2 atmosphere. Before infection, cells were plated in 96 well plates at 1 X 104 cells per well and differentiated with PMA (30 ng/ml) for a period of 48 hrs. Bacteria were grown in Middlebrooke 7H9 broth supplemented with 10% ADC, 0.4% Glycerol and 0.05% Tween 80 until the mid-log phase. The bacteria were then harvested, washed with RPMI and re-suspended in the same media.
  • the suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments. Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to ⁇ 100 X 106 bacteria).
  • PMA-differentiated THP-1 cells were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5%C0 2 . After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200 ⁇ g/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment.
  • Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i.
  • the cells were lysed in 50 ⁇ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 ⁇ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently How in parallel tracks along the agar surface.
  • Example 5 Determination of the effect of the compounds of the present invention on lipid bodies.
  • THP-1 cells were seeded onto #1 thickness, 12 mm diameter glass cover-slips in 24-well tissue culture plates at a density of 0.3x106 cells per cover slip. These cells were then infected M. tb (H37Rv) at a MOI of 10 and incubated for 4h at 370 C in 5% C02. Extracellular bacteria were removed by washing and subsequently by supplementing the medium with 200 ⁇ g/ml amikacin for 2h. SPR1 13 was added in increasing concentrations immediately after the amikacin treatment, and the medium containing the appropriate inhibitor was replenished at 16h and 40h post infection. At 48hrs post infection cells were fixed with 3.7% para-formaldehyde and washed with PBS.
  • HCS LipidTox Red neutral lipid stain diluted 1 : 1000 in PBS was added to the cells for 30 min.
  • the cell nuclei were stained using 300nM DAPI solution (in H20) for 5 min and then washed. Stained cells were observed with a Nikon EclipseTi-E laser scanning confocal microscope equipped with 60X/1.4NA Plan Apochromat DIC objective lens.
  • DAPI and Lipid Tox were excited at 408 nm and 543 nm with a blue diode and a Helium-Neon laser respectively. The emissions were recorded through emission filters set at 450 and 605/75 nm. Images were acquired with a scanning mode format of 512 x 512 pixels.
  • Example 6 Effect of compounds against different mycobacterial strains.
  • THP-1 cells independently infected with r M.tb strains [JAL2287, JAL2261 , XDR]. Addition of the media containing compound was performed at 16 hr and the medium containing the appropriate dose of compound was refreshed every 24 hr up to the 64 hr time point. At the end of the total culture period of 90 hr, cells were lysed and CFUs were determined and results are as shown graphically in Figure 3.
  • the cellular Potency of compound 1085 was measured in MTB infected THP1 and EC50 of H37Rv was 0.5nM and MYC431 and JAL2287 were 0.1 nM.
  • the graph shows that compound inhibited all the mycobacterial strains at concentration of 0.01 to 500nM.
  • Example 7 Effect of compounds on c-AMP levels.
  • THP-1 macrophages were incubated with compd. 1085 at the indicated concentrations for 30 min, following which 3-hydroxybutyric acid. (3HBA, lOuM), a GPR109A agonist, was added to cells for 90 min. In the absence of compound 1085, 3HBA reduces intracellular cAMP levels while compound 1085 inhibits the activity in a dose dependent manner. The results are represented at Figure 4.
  • Example 8 Co-localization of M. tuberculosis with degradative vesicles: acidified lysosomes and autophagosomes in the presence of compound 1085
  • THP-1 cells were seeded onto glass cover-slips in 24-well tissue culture plates at a density of 0.3x 10 6 cells per cover slip. These cells were then infected GFP- tagged M. tb (H37Rv-GFP) at a MOI of 10 and incubated for 4h at 37° C in 5% C0 2 . Extracellular bacteria were removed by washing and subsequently by supplementing the medium with 200 ⁇ g/ml Amikacin for 2hr. compound 1085 was added at 100 nM concentration immediately after the amikacin treatment, and the medium containing the compound was replenished at 16h and 40h post infection.
  • GFP- tagged M. tb H37Rv-GFP
  • Tuberculosis modulates both these degradative pathways in order to ensure its continued survival within the macrophage. Interventions which lead to activation of these pathways in infected macrophages will lead to targeted killing of intracellular M. Tuberculosis and thus reduce mycobacterial load.
  • the significance of the experiments done with compound 1085 is that treatment of infected macrophages with this compound leads to an increased co localization of mycobacteria with these degradative vesicles which is reflected by the increased value of the co localization coefficient (higher value of co localization coefficient indicates a higher percentage of bacteria present inside these degradative vesicles). The bacteria present inside these vesicles upon compound 1085 treatment are thus primed to be subsequently killed which in turn is reflected in the lower in vitro cfu's obtained with compound 1085.
  • Example 9 GPR109A specific effect of compound no. 1085 on cellular lipid bodies
  • THP-1 cells were seeded onto glass cover-slips in 24-well tissue culture plates at a density of 0.3xl 0 6 cells per cover slip.
  • Ligand for GPR109A, 3-HB (10 uM) was added to the cells and in parallel sets. Compd. 1085 was added in increasing concentrations.
  • At 48h post 3HB addition cells were fixed with 3.7% para-formaldehyde and washed with PBS.
  • HCS LipidTox Red neutral lipid stain diluted 1 : 1000 in PBS was added to the cells for 30 min. The cell nuclei were stained using 300nM DAPI solution (in H 2 0) for 5 min and then washed. Stained cells were observed with a laser scanning confocal microscope equipped with Apochromat DIC objective lens.
  • DAPI and Lipid Tox were excited at 408 nra and 543 nm with a blue diode and a Helium-Neon laser respectively.
  • the emissions were recorded through emission filters set at 450 and 605/75 nm. Images were acquired with a scanning mode format of 512 x 512 pixels.
  • the transmission and detector gains were set to achieve best signal to noise ratios and the laser powers were tuned to limit bleaching fluorescence. All images were quantified and the results are graphically depicted in Figure 6 which demonstrates that significant effect on average fluorescent intensity was observed in presence of compound 1085 representing decrease in the cellular lipid body.
  • Example 10 Effect of compound 1085 on intracellular mycobacterial load in THP-1 macrophages infected individually with 8 different strains of M. tuberculosis
  • the human monocyte/ macrophage cell line THP-1 was cultured in RPMI 1640 supplemented with 10% FCS and were maintained between 2 and 10 X 10 5 cells per ml at 37°C in a humidified, 5% C0 2 atmosphere. Before infection, cells were plated in 96 well plates at 1 X 10 4 cells per well and differentiated with PMA (30 ng/ml) for a period of 48 hrs. Bacteria were grown in Middlebrooke 7H9 broth supplemented with 10% ADC (Becton Dickinson), 0.4% Glycerol and 0.05% Tween 80 until the mid-log phase. The bacteria were then harvested, washed with RPMI and re-suspended in the same media.
  • ADC Becton Dickinson
  • the suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments. Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to ⁇ 100 X 10 6 bacteria).
  • PMA-differentiated THP-1 cells were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5% C0 2 . After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200 ⁇ g/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment.
  • Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i.
  • the cells were lysed in 50 ⁇ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 ⁇ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently flow in parallel tracks along the agar surface.
  • Example 11 Effect of combinations of compound 1085 with known anti-mycobacterial antibiotics on intracellular mycobacterial load in THP-1 macrophages infected with M. tuberculosis H37Rv.
  • the human monocyte/ macrophage cell line THP-1 was cultured in RPMI 1640 (Gibco Laboratories) supplemented with 10% FCS (Hyclone) and were maintained between 2 and 10 X 10 5 cells per ml at 37°C in a humidified, 5% C0 2 atmosphere. Before infection, cells were plated in 96 well plates at 1 X 10 4 cells per well and differentiated with PMA (30 ng/ml) for a period of 48 hrs. Bacteria were grown in Middlebrooke 7H9 broth (Difco) supplemented with 10% ADC (Becton Dickinson), 0.4% Glycerol and 0.05% Tween 80 until the mid-log phase.
  • FCS Hyclone
  • the bacteria were then harvested, washed with RPMI and resuspended in the same media.
  • the suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments.
  • Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to ⁇ 100 X 10 6 bacteria).
  • PMA-differentiated THP-1 cells were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5% C0 2 . After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200 ⁇ g/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment.
  • Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i.
  • the cells were lysed in 50 ⁇ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H 1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 ⁇ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently flow in parallel tracks along the agar surface.
  • the plates were then allowed to dry and subsequently incubated in a humidified incubator at 37°C. Colonies were counted on the 14th day and converted into cfu/well.
  • the Figure 8 shows that the compound 1085 does not negatively affect the activities of the known anti TB antibiotics and in some cases there might be additive/synergistic effects.
  • Example 12 Compound 1085 treatment in mice (oral dosing)
  • mice Female BALB/c mice 4-6 wk of age at 5/group were infected with MDR- M. tb (JAL2287) through the aerosol route by delivering between 150-200 bacteria per lung during 30 min of exposure.
  • MDR- M. tb JAL2287
  • One group of mice was sacrificed 24 h later and lung homogenates were plated onto 7H1 1 agar plates for confirming infection.
  • compoundl 085 treatment was initiated by delivering the compound orally.
  • Individual groups of mice were treated at the following doses: 100, 30, and 10 mg/kg body weight/ day (1085 was solubilized in PEG400). At fourteen days following treatment, mice were sacrificed and lung and spleen enriched using a homogenizer.
  • Example 13 Compound 1085 + ATT combination treatment in mice (oral dosing)
  • mice Female BALB/c mice 4-6 wk of age at 5/group were infected with drug susceptible M. tb (H37Rv) through the aerosol route by delivering between 150-200 bacteria per lung during 30 min of exposure.
  • One group of mice was sacrificed 24 h later and lung homogenates were plated onto 7H1 1 agar plates for confirming infection.
  • oral drug treatment was initiated with a single dose per day.
  • One group received Anti-TB therapy, ATT (Isoniazid: 1.5mg/kg + Rifampicin: lmg/kg + Pyrazinamide: 1 .5mg/kg + Ethambutol : 1.5mg/kg), one group received compd.
  • ATT Anti-TB therapy
  • mice were sacrificed along with a control (mocka treated) group and lungs enriched using a homogenizer. An aliquot (100 ⁇ ) of the serially diluted homogenate (10 " & 10 " ) was plated onto 7H1 1 agar plates for determining the mycobacterial load. The CFU's were counted at 18 days post plating on the agar plates. Combination treatment of compd. 1085 with ATT demonstrates significant reduction in lung CFU as depicted in Figure 10. The data is represented in below Table7.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to novel compounds of formula (1): The present invention also discloses compounds of formula (1) along with other pharmaceutical acceptable excipients and use of the compounds as anti-tubercular agents.

Description

NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS FIELD OF THE INVENTION
The present invention relates to novel compounds useful as anti-tubercular agents. More particularly, the present invention relates to substituted derivatives, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of tuberculosis.
BACKGROUND OF THE INVENTION
Tuberculosis causes nearly two million deaths annually. Recent years have witnessed a resurgence of efforts directed at tuberculosis (TB) drug research and development. An analysis of the chronology of anti-tuberculosis therapy suggests a renewed interest in tuberculosis research. Since the 1960s and 70s same generation of antibiotics or their derivatives are being used against Mycobacterium tuberculosis even though there is resistance against the drugs with the development of drug resistant strains such as Multidrug resistance TB (MDR-TB)which are resistant to at least isoniazid (INH) and rifampicin (RMP), the two most powerful first-line treatment anti-TB drugs; extensively drug resistance TB (XDR-TB)which are resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs such as amikacin, kanamycin, or capreomycin and totally drug resistance TB (TDR-TB) which are resistant to all first and second line drugs tested such as isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, ciprofloxacin, capreomycin, kanamycin.
India has the world's one of the highest burden of tuberculosis, wherein MDR tuberculosis accounts for nearly 5 lakhs cases annually which have been increased by more than 6% in the past 10 years.
It is said that M. tuberculosis develops resistance to drugs by induced or spontaneous mutation of its genome. It is also hypothesized that in case of certain drugs the bacterial cell wall, does not permit adequate permeability, thereby resulting in inadequate/minor amount of drug entering the bacteria. Such amount is insufficient to kill the bacteria, but the presence of minor amount, induces the bacteria to become resistant to the same. It is also hypothesized that M. tuberculosis acquires resistance by modification of its enzyme by unknown mechanisms. Traditional antitubercular drugs administered via oral route, act by inhibiting the synthesis of mycolic acid and/or by inhibiting the mycobacterial arabinosyltransferase, an essential component of mycobacterial cell wall. Few systemic antitubercular drugs also act by crossing the lipid bilayer and bind to one of the ribosome sub-unit, inhibiting the protein synthesis. Based on mechanism of action of these drugs, these drugs have a high probability of inducing mutation and/or have problems of permeability, increasing the chances of drug resistant strains.
G-protein coupled receptors such as GPR109A also plays an important role in tuberculosis. GPR109A receptor is located on the cell surface and inhibits adenylyl cyclase along with consequent suppression of P A-signaling resulting in reduced triglyceride turnover which is further responsible for accumulation of lipid body inside the cell. Increase in the concentration of lipid body inside the cell favors the growth of M. tuberculosis and prevents respiratory burst. A GPR109A inhibitor prevents the formation of lipid body by creating a hostile environment for the tuberculosis and thus induces respiratory burst. Host macrophages infected by M. tuberculosis acquire foamy phenotype characterized by the intracellular accumulation of lipid bodies induced by pathogen through modulation of lipolysis of neutral lipids. This dysregulation influences the lipolysis by modulating the cAMP dependent signaling pathway.
Current resistant tuberculosis treatment, has greater risk of side effects and lasts for 18-24 months and target processes or enzymes within M. tuberculosis but suffers from the risk of generating newer variants exhibiting drug resistance. Since, M. tuberculosis survives within the human macrophage through modulation of a range of host cellular processes hence, a pharmacological target within the host that has been co-opted by M. tuberculosis for its survival should be a breakthrough approach for therapy. Additionally such an approach should be insensitive to whether the infecting strain was drug sensitive or drug resistant and preclude the development of resistance.
OBJECT OF THE INVENTION
An object of the invention is to provide compounds useful as anti -tubercular agents. SUMMARY OF THE INVENTION
The present invention provides novel ula 1 :
Figure imgf000005_0001
Formula 1
wherein,
X is selected from O, NH or N(alkyl);
Ri and R2are independently selected from hydrogen, deuterium, hydroxyl, Cj-io straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci.6alkoxy, aryl, amino, NH(alkyl), N(alkyl)2 OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group comprising O, N or S; or Ri and R2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group comprising O, N or S;
R3isselected from hydrogen, hydroxyl, Ci-6 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci^alkoxy, aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic rings elected from:
Figure imgf000005_0002
X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, O or S. The heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH- aralkyl;-
R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium,
CI -6 alkoxy, amino, NH(alkyl), N(alkyl)2, -COOR8, CONR8R9;
R5 is hydrogen, hydroxy, Cl-6alkyl, Cl-6alkoxy, amino, NH(alkyl), N(alkyl)2;
R6 and R7 are independently selected from the group comprising hydrogen, CI -10 alkyl, -
COR8, -CH20COR8, -CH20CONHR8R9, -COOR8, -CONR8R9, -S02R8, aryl, aralkyl;
R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl;
n is 1 ,2, or 3. and salts, hydrates and stereoisomers thereof. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1, depicts the effects of the compounds of the present invention in MYC-431 infected THP-1 macrophages
Figure 2, depicts the effects of the compounds of the present invention on Lipid Bodies Figure 3 depicts the potency of compound 1085 of the present invention in Cellular M.tb
Figure 4, represents the effect of compound 1085 on adenylyl cyclase (c-AMP) in THP-1 macrophages
Figure 5a and 5b, represents the Co-localization of M. tuberculosis with degradative vesicles: acidified lysosomes and autophagosomes in the presence of compound 1085
Figure 6, represents the effect of compound 1085 on cellular lipid body
Figure 7, represents the effect of compound 1085 on various mycobacterial strains
Figure 8, represents the effect of compound 1085 on the mycobacterial growth alone and in combination with other pharmaceutical agents
Figure 9a and 9b, represents the pharmacokinetic parameters of compound 1085 administered via intraperitoneal route
Figure 10, represents the combination treatment of compound 1085 with Antituberculer therapy (ATT) DETAILED DESCRIPTION OF THE INVENTION
A. Compounds of the present invention:
Accordingly, the present invention provides novel compound of Formula 1 as antitubercular agents.
The present invention relates to novel compounds of Formula (1 ):
Figure imgf000007_0001
Formula 1
wherein,
X is selected from O or NH;
R) and R2 are independently selected from hydrogen, deuterium, hydroxyl, CMO straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci-6alkoxy, aryl, amino, NH(alkyl), N(alkyl)2j OCOR5, heteroaryl containing 1 -3 heteroatoms selected from the group comprising O, N or S; or Ri and R2 may combined to form an aryl or a heteroaryl ring containing 1 -3 heteroatoms selected from the group comprising 0, N or S;
R3 is selected from hydrogen, hydroxyl, Ci-6 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci-6 alkoxy, aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
Figure imgf000007_0002
X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, 0 or S. The heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH- aralkyl;
R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium,
CI -6 alkoxy, amino, NH(alkyl), N(alkyl)2, -COOR8, CONR8R9;
R5 is hydrogen, hydroxy, Cl-6alkyl, Cl-6alkoxy, amino, NH(alkyl), N(alkyl)2;
R6 and R7 are independently selected from the group comprising hydrogen, CI -10 alkyl, -
COR8, -CH20COR8, -CH20CONHR8R9, -COOR8, -CONR8R9, -S02R8, aryl, aralkyl;
R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl;
n is 1 ,2, or 3;
and salts, hydrates and stereoisomers thereof.
Further, the present invention relates to novel compounds of Formula (1):
Figure imgf000008_0001
Formula 1
wherein
X is NH;
Ri and R2 are selected from hydrogen, hydroxyl, C MO alkyl, C1-6alkoxy;
R3 is selected from substituted aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected fro
Figure imgf000008_0002
R4 is selected from hydrogen, deuterium, halogen, Ci-6 straight chain or branched chain alkyl, Ci-6 alkoxy, amino, NH(alkyl), N(alkyl)2;
R6 and R7 are independently selected from hydrogen, Ci-10 alkyl, -COR8, -CH2OCOR8, - CH2OCONHR8R9, -COOR8, -CONR8R9, -S02R8, phenyl, benzyl;
R8 and R9 are independently selected from hydrogen or C1-6 straight chain or branched chain alkyl;
n is 1 ,2 or 3.
and salts, hydrates and stereoisomers thereof.
The term "alkyl" refers to a linear or branched saturated monovalent hydrocarbon, wherein the alkylene may optionally be substituted as described herein. The term "alkyl" also encompasses both linear and branched alkyl, unless otherwise specified. In certain embodiments, the alkyl is a linear saturated monovalent hydrocarbon that has the specified number of carbon atoms, or branched saturated monovalent hydrocarbon of specified number of carbon atoms. As used herein, linear CI- C6 and branched C3- C6 alkyl groups are also referred as "lower alkyl. "Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (including allisomeric forms), n-propyl, isopropyl, butyl (including all isomeric forms), rc-butyl, isobutyl, sec-butyl, t-buly\, pentyl (including all isomeric forms), and hexyl (including all isomeric forms). For example, CI - C6 alkyl refers to a linear saturated monovalent hydrocarbon of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon of 3 to 6 carbon atoms.
The term "aryl" refers to a monocyclic aromatic group and/or multicyclic monovalent aromatic group that contain at least one aromatic hydrocarbon ring. In certain embodiments, the aryl has from 6 to 20 (C6 - C20), from 6 to 15 (C6 - CI 5), or from 6 to 10 (C6 - CIO) ring atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl. Aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). In certain embodiments, aryl may be optionally substituted as described herein. The term "alkoxy" refers to the group R'0~ wherein R' is alkyl. The term "lower alkoxy" refers to alkoxy groups having from 1 to 3 carbon atoms; examples include methoxy, ethoxy, isopropoxy, and the like.
The term "cycloalkyl" as used herein refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. Cycloalkyl can include any number of carbons, such as C3-6, C4-6, C5-6, C3-8, C4-8, C5-8, and C6 8. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2]bicyclooctane, decahydronaphthalene and adamantane. Cycloalkyl groups can also be partially unsaturated, having one or more double bonds in the ring. Representative cycloalkyl groups that are partially unsaturated include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1 ,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4- and 1 ,5-isomers), norbornene, and norbornadiene. Unless otherwise stated, cycloalkyl groups are unsubstituted. A "substituted cycloalkyl" group can be substituted with one or more moieties selected from halo, hydroxy, amino, alkylamino, nitro, cyano, and alkoxy.
The term "aralkyl" or "aryl-alkyl" refers to a monovalent alkyl group substituted with aryl. Incertain embodiments, the alkyl and aryl moieties are optionally substituted as described herein.
The term "heteroaryl" refers to a monocyclic aromatic group and/or multicyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms independently selected from 0, S, and N. Each ring of a heteroaryl group may contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl,imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl,pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl,and triazolyl. Examples of bicyclic heteroaryl groups include, but are not limited to,benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Examples of tricyclic heteroaryl groupsinclude, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, heteroaryl may also be optionally substituted as described herein.
The term heteroaralkyl refers to an aralkyl group as defined above, in which one or more (preferably 1 , 2, 3 or 4) carbon atoms have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulphur atom (preferably oxygen, sulphur or nitrogen), that is to say groups that in accordance with the above definitions contain both aryl or heteroaryl and alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups. A hetero-aralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) with from 5 or 6 to 10 carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups having from 1 or 2 to 6 carbon atoms and/or a cycloalkyl group having 5 or 6 ring carbon atoms, with 1 , 2, 3 or 4 of those carbon atoms having been replaced by oxygen, sulphur or nitrogen atoms. Examples are aryl-heteroalkyl, aryl-heterocycloalkyl, aryl- heterocycloalkenyl, arylalkyl-heterocycloalkyl, arylalkenyl-heterocycloalkyl, arylalkynyl- heterocycloalkyl, arylalkyl-heterocycloalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroaryl-heteroalkyl, heteroarylcyclo-alkyl, heteroarylcycloalkenyl, heteroaryl-heterocycloalkyl, heteroaryl-heterocycloalkenyl, heteroarylalkylcycloalkyl, _ g _ heteroarylalkyl-heterocycloalkenyl, heteroaryl-heteroalkyl-cycloalkyl, heteroaryl- heteroalkylcycloalkenyl and hetero-aryl-heteroalkyl-heterocycloalkyl groups, the cyclic groups being saturated or mono-, di- or tri-unsaturated. Specific examples are the tetrahydroisoquinolinyl, benzoyl, 2- or 3-ethylindolyl, 4-methylpyridino, 2-, 3- or 4- methoxyphenyl, 4-ethoxyphenyl and 2-, 3- or 4-carboxylphenylalkyl groups.
The term "heterocyclyl" or "heterocyclic" refers to a monocyclic non-aromatic ring system and/or multicyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from 0, S, or N; and the remaining ring atoms are carbon atoms. In certain embodiments, the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. In certain embodiments, the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused or bridged ring system, and in which thenitrogen or sulfur atoms may be optionally oxidized, the nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic. The heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in thecreation of a stable compound. Examples of such heterocyclic compounds include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, p-carbolinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1 ,3,5-trithianyl. In certain embodiments, heterocyclic may also be optionally substituted as described herein.
The term "halogen", "halide" or "halo" refers to fluorine, chlorine, bromine, and iodine.
The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur, phosphorus and selenium. The term "aromatic", as used herein, refers to an unsatured cyclic moiety that has an aromatic character. The term is intended to encompass both hydrocarbon aromatic compounds and heteroaromatic compounds. The terms "hydrocarbon aromatic ring" or "hydrocarbon aromatic compound" refer to an aromatic ring or compound in which the aromatic moieties have only carbon and hydrogen atoms. The terms "heteroaromatic ring" or "heteroaromatic compound' refer to an aromatic ring or compound wherein in at least one aromatic moiety one or more of the carbon atoms within the cyclic group has been replaced by another atom, such as nitrogen, oxygen, sulfur, or the like. The term "non-aromatic", as used herein, refers to a cyclic moiety, that may be unsaturated, but that does not have an aromatic character.
The term "substituted" refers to where hydrogen radical on a molecule has been replaced by another atom radical, a functional group radical or a moiety radical; these radicals being generally referred to as "substituents."
The term "optionally substituted" is intended to mean that a group, such as an alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, dialkylamino, carboxamido, cycloalkyl, cycloalkylene, aryl, arylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene, may be substituted with one or more substituents independently selected from,e.g., (a) CI - C6 alkyl, C2 - C6 alkenyl, C2 - C6 alkynyl, C3 - C7 cycloalkyl, C6 - C14 aryl, C7 - C15aralkyl, heteroaryl, and heterocyclyl, each optionally substituted with one or more substituents; and (b) halo, cyano (-CN), nitro (-N02),-C(O)R3 , -C(0)OR3 , - C(0)NRbRC , -C(NR3)NR)RC , -OR3 , -OC(0)R3 , -OC(0)OR3, -OC(0)NRbRC, - OC(=NR3)NR)RC, -OS(0)R3, -OS(0)2R3, -OS(0)NRbRC, -OS(0)2NRbRc, -NRbRc,- NR3C(0)Rd„ -NR3C(0)ORd, -NR3 C(0)NRbRC , -NR3 C(=NRd)NRbRC , -NR3S(0)Rd, - NR3S(0)2Rd, -NR3S(0)NRbRC, -NR3S(0)NRbRc, -SR3, -S(0)R3, -S(0)2R3, - S(0)NRbRC, and -S(0)2NRbRC, wherein each R3, Rb, Re, and Rd isindependently (i) hydrogen; (ii) C I - C6 alkyl, C2 - C6 alkenyl, C2 - C6 alkynyl, C3 - C7cycloalkyl, C6 - C14 aryl, C7 - C 15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents; or (iii) Rb and Re together with the N atom to which they are attached form heteroaryl or heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents. As used herein, all groups that may be substituted are "optionally substituted," unless otherwise specified.
The use of terms "a" and "an" and "the" and similar references in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contraindicated by context.
The term "salt(s)", as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. Zwitterions (internal or inner salts) are included within the term "salt(s)" as used herein (and may be formed, for example, where the R substituents comprise a basic moiety such as an amino group). Also included herein are quaternary ammonium salts such as alkyl ammonium salts. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred.
The term "pharmaceutically acceptable salts" refers to the acid addition salt compound formed with a suitable acid selected from an inorganic acid such as hydrochloric acid, hydrobromic acid; or an organic acid such as benzene sulfonic acid, maleic acid, oxalic acid, fumaric acid, succinic acid, p-toluenesulfonic acid and malic acid.
The term "hydrate" as used herein designates a crystalline molecular compound in which water molecules are incorporated into the crystal lattice. Generally speaking, a hydrate thus designates a crystalline form of a molecular compound, whereby the only further molecules incorporated into the crystal lattice are water molecules.
The term "stereoisomer' s" refers to at least two compounds having the same molecular formula and connectivity of atoms, but having a different arrangement of atoms in a three- dimensional space. In view of the present disclosure, a stereoisomer can be, for example, an enantiomer, a diastereomer, or a meso compound.
The term "prophylactic" as used herein refers variously to medicaments, amounts or quantities, methods, uses and effects, etc., that prevent and/or aid in preventing infections.
The term "therapeutic" as used herein refers to preventing, ameliorating, treating, improving, or curing a disease or condition.
The term "Directly Observed Treatment Short-Course" (DOTS) refers to treatment regimen consisting of a four-drug such as Rifampicin, Isoniazid, Ethambutol and Pyrazinamide) intensive phase of two months, followed by a two-drug (Rifampicin and Isoniazid) continuation phase of four months.
The term "Multidrug resistance Tuberculosis" (MDR-TB) as used herein refers to tuberculosis which are resistant to atleast isoniazid (INH) and rifampicin (RMP), the two most powerful first-line treatment anti-Tuberculosis drugs. The term "Extensively drug resistance Tuberculosis" (XDR-TB) as used herein refers to the tuberculosis which are resistant to atleast three of the six classes of second line antituberculosis drugs as well as isoniazid and rifampicin, plus any fluoroquinolone and at least one of three injectable second-line drugs such asamikacin, kanamycin, or capreomycin.
The term "Totally Drug Resistance Tuberculosis" (TDR-TB) as used herein refers to the tuberculosis which are resistant to all first and second line drugs tested such as isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, ciprofloxacin, capreomycin, kanamycin.
The term"H37Rv" as used herein refers to a pathogenic M. tuberculosis strain that has been sequenced.
The term "JAL2287" as used herein refers to the MDR (multi drug resistant) strainof M tuberculosis
The term "MYC431 " as used herein refers to the XDR (extensive drug resistant) strain of M. tuberculosis
The term "GPR109A" as used herein refers to the G-protein coupled receptor GPR109A.
The present invention provides compound represented by formula (1) that inhibits mycobacterium colony growth alone or in combination with DOTS (Directly Observed Treatment Short Course) therapy.
The compounds of the present invention may be illustrated but not limited to the examples as provided at Table 1. Table 1 : Illustrative compounds of present invention
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
The present invention also provides for compounds of formula (1) as below: i. 1 -methylpiperidin-3-yl-2-hydroxy-2,2-diphenylacetate; ii. 3-(2-hydroxy-2,2-diphenylacetoxy)-l-(((isopropylcarbamoyl)oxy)methyl)-l- methylpiperidin- 1 -ium; iii. piperidin-3-yl 2-hydroxy-2,2-diphenylacetate; iv. l-benzylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate; v. 1 -(methylsulfonyl)piperidin-3-yl 2-hydroxy-2,2-diphenylacetate; vi. 1 -(dimethylcarbamoyl)piperidin-3-yl 2-hydroxy-2,2-diphenylacetate; vii. 1 -benzylpiperidin-4-yl 2-hydroxy-2,2-diphenylacetate; viii. 3-(2-hydroxy-2,2-diphenylacetoxy)-l -methylquinuclidin-l-ium; ix. l-benzylpyrrolidin-3-yl 2-hydroxy-2,2-diphenylacetate; x. l-ethylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xi. 1 -(isopropylcarbamoyl)piperidin-3-yl 2-hydroxy-2,2-diphenylacetate; xii. l -propylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xiii. 1 -methylpiperidin-4-yl 2-hydroxy-2,2-diphenylacetate;
xiv. l-benzylazetidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xv. l-acetylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xvi. 2-hydroxy-2,2-diphenyl-N-(piperidin-3-yl)acetamide;
xvii . N-( 1 -benzylpiperidin-4-yl)-2-hydroxy-2,2-diphenylacetamide;
xviii. l-methylpyrrolidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xix. quinuclidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xx. 2-hydroxy-N-(l -methylpiperidin-3-yl)-2,2-diphenylacetamide;
xxi. N-( 1 -benzylpiperidin-4-yl)-2-hydroxy-2,2-diphenylacetamide;
xxii . N-( 1 -benzylazetidin-3 -yl)-2-hydroxy-2,2-diphenylacetamide;
xxiii. azetidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxiv. (S)-l -benzylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxv. (R)-l -benzylpiperidin-3 -yl 2-hydroxy-2,2-diphenylacetate;
xxvi. (S)-l-methylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxvii. (R)-l -methylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxviii. (R)-N-( 1 -benzylpiperidin-3-yl)-2-hydroxy-2,2-diphenylacetamide; xxix. (R)-N-(l -benzylpiperidin-3-yl)-2-hydroxy-2,2-diphenylacetamide; xxx. 2-hydroxy-2,2-diphenyl-N-(piperidin-4-yl)acetamide;
xxxi. (S)-2-hydroxy-N-(l-methylpiperidin-3-yl)-2,2-diphenylacetamide; xxxii. (R)-2-hydroxy-N-(l-methylpiperidin-3-yl)-2,2-diphenylacetamide; xxxiii. l -benzylazetidin-3-yl 2-hydroxy-2-phenylpropanoate;
xxxi v. (R)-N-( 1 -benzylpiperidin-3 -yl)-2,2-diphenylacetamide;
xxxv. N-((S)- 1 -benzylpiperidin-3 -yl)-2-hydroxy-2-phenylacetamide;
xxxvi. N-((R)- 1 -benzylpiperidin-3 -yl)-2-hydroxy-2-phenylpropanamide; xxxvii. (R)-(R)- 1 -methylpiperidin-3-yl 2-hydroxy-2-phenylacetate;
xxxviii. (R)-(S)- 1 -methylpiperidin-3-yl 2-hydroxy-2-phenylacetate;
xxxix. (S)-(R)-l-methylpiperidin-3-yl 2-hydroxy-2-phenylacetate;
xl. (S)-(S)-l -methylpiperidin-3-yl 2-hydroxy-2-phenylacetate;
xli. (R)-l -methylpiperidin-4-yl 2-hydroxy-2-phenylacetate;
xlii. (S)-2-hydroxy-N-( 1 -methylpiperidin-4-yl)-2-phenylacetamide;
xliii. (R)-2-hydroxy-N-(l-methylpiperidin-4-yl)-2-phenylacetamide;
xliv. (R)-2-hydroxy-N-((R)- 1 -methylpiperidin-3-yl)-2-phenylacetamide; xlv. (R)-2-hydroxy-N-((S)-l-methylpiperidin-3-yl)-2-phenylacetamide; xlvi. (S)-2-hydroxy-2-phenyl-N-(pyridin-3-yl)acetamide;
xlvii. (S)-l-methylpiperidin-4-yl 2-hydroxy-2-phenylacetate;
xlviii. (S)-l -benzylazetidin-3-yl 2-hydroxy-2-phenylacetate;
xlix. (S)-(R)-quinuclidin-3-yl 2-hydroxy-2-phenylacetate;
1. (S)-(S)-quinuclidin-3-yl 2-hydroxy-2-phenylacetate;
li. (R)-N-(l -benzylpiperidin-4-yl)-2-hydroxy-2-phenylacetamide;
Hi. (S)-N-(l -benzylpiperidin-4-yl)-2-hydroxy-2-phenylacetamide;
liii. (R)-3-((R)-2-hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium; liv. (S)-3 -((R)-2-hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium; lv. (R)-2-hydroxy-2-phenyl-N-(pyridin-3-yl)acetamide;
lvi. (R)-(S)-l-methylpiperidin-3-yl 2-acetoxy-2-phenylacetate;
lvii. (R)-(R)- 1 -methylpyrrolidin-3-yl 2-hydroxy-2-phenylacetate;
lviii. (R)-(S)-l-methylpyrrolidin-3-yl 2-hydroxy-2-phenylacetate;
lix. (S)-(R)-l-methylpiperidin-3-yl 2-methoxy-2-phenylacetate;
lx. 2-methoxy-2-phenylacetic acid;
lxi. (R)-2-hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
lxii. (R)-piperidin-4-yl 2-hydroxy-2-phenylacetate;
lxiii. (R)-3 -(2-hydroxy-2,2-diphenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxiv. (R)-3-(2-hydroxy-2,2-diphenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lx v. (R)-3-((R)-2-hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxvi. (R)-3-((R)-2-hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxvii . (S)-(R)- 1 -methylpiperidin-3 -yl 2-methoxy-2-phenylacetate;
lxviii. (S)-(S)-l-methylpiperidin-3-yl 2-methoxy-2-phenylacetate;
lxix. (S)-2-hydroxy-N-((R)-l -methylpiperidin-3-yl)-2-phenylacetamide;
lxx. (S)-2-hydroxy-N-((S)-l -methylpiperidin-3-yl)-2-phenylacetamide;
lxxi . 3-(2,2-diphenylacetamido)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxxii . (2S)-1 -benzyl-2-((2,2-diphenylacetamido)methyl)- 1 -methylpyrrolidin- 1 -ium; lxxiii. 3 -(2-hydroxy-2,2-diphenylacetamido)- 1,1 -dimethylpiperidin- 1 -ium;
lxxiv. (R)-2-methoxy-l -((S)-3-methylmorpholino)-2-phenylethanone;
lxxv. (R)-2-methoxy- 1 -((R)-3 -methylmo holino)-2-phenylethanone;
lxxvi. (R)-l-((2 ,3S)-2,3-dimethylmo holino)-2-methoxy-2-phenylethanone; lxxvii. (S)-2-methoxy-l-((S)-3-methylmorpholino)-2-phenylethanone; lxxviii. ( 1 R,3R)- 1 -benzyl-3-(2,2-diphenylacetamido)- 1 -methylpiperidin- 1 -ium; lxxix. (l S,3R)-l -benzyl-3-(2,2-diphenylacetamido)-l-methylpiperidin-l -ium; lxxx. (l S,3R)-l-benzyl-3-(2,2-diphenylacetamido)-l-methylpiperidin-l -ium; lxxxi. ( 1 R,3R)- 1 -benzyl-3-(2,2-diphenylacetamido)- 1 -methylpiperidin- 1 -ium; lxxxii. l -(3-(benzylamino)piperidin-l-yl)-2,2-diphenylethanone; lxxxiii. N-((l -benzylpyrrolidin-2-yl)methyl)-2,2-diphenylacetamide; lxxxi v. 1 -benzyl-2-((2,2-diphenylacetamido)methyl)- 1 -methylpyrrolidin- 1 -ium; lxxxv. (R)-2-methoxy-2-phenyl-N-(piperidin-4-yl)acetamide; lxxxvi. . 2-hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide; lxxxvii. (S)-2-hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide; lxxxviii. (S)-2-methoxy-2-phenyl-N-(piperidin-4-yl)acetamide; lxxxix. 2-hydroxy-2-phenyl-N-(piperidin-4-yl)propanamide; xc. 2-(3-bromo-2,6-difluorophenyl)-2-hydroxy-N-(piperidin-4-yl)acetamide; xci. (R)-2-methoxy-N-methyl-2-phenyl-N-(piperidin-4-yl)acetamide; xcii. (R)-N-(l -benzylpiperidin-4-yl)-2-methoxy-N-methyl-2-phenylacetamide; xciii. (S)-l-benzylpiperidin-4-yl 2-methoxy-2-phenylacetate; xciv. (R)-ethyl 4-(2-methoxy-2-phenylacetamido)piperidine-l -carboxylate;
B. Salts and Isomers and Counter Ions
The present invention includes within its scope the salts and isomers. Compounds of the present invention after being novel may in some cases form salts which are also within the scope of this invention. All stereoisomer' s of the present compounds, such as those which may exist due to asymmetric carbons on the R substituents of the compound, including enantiomeric and diastereomeric forms, are contemplated within the scope of this invention.
The present invention may also optionally envisage within its scope the effect of selection of suitable counter ions. The present invention includes in its scope, the modification of deuterated compounds. Deuterated compounds are those wherein the compounds have selective incorporation of deuterium in place of hydrogen.
The Compounds of the present invention may be present in their enantiomeric pure forms or their mixtures.
C. Synthesis of the Compounds of the Present Invention
The compounds of the present invention may be synthesized by the any of the synthetic schemes as shown below:
General Synthetic Scheme
Figure imgf000035_0001
The compounds of present invention may be synthesized by coupling A with B in the presence of (i) as depicted in the scheme above.
X is selected from O, NH or N(alkyl);
Ri and R2are independently selected from hydrogen, deuterium, hydroxyl, C O straight chain or branched chain alkyl, 3-7 membered cycloalkyl, C]-6alkoxy, aryl, amino, NH(alkyl), N(alkyl)2 OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group comprising O, N or S; or Ri and R2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group comprising O, N or S; R3isselected from hydrogen, hydroxyl, Ci-6 straight chain or branched chain alkyl, 3-7 membered
Figure imgf000036_0001
aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
Figure imgf000036_0002
X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, O or S. The heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH- aralkyl;
R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, CI -6 alkoxy, amino, NH(alkyl), N(alkyl)2, -COOR8, CONR8R9;
R5 is hydrogen, hydroxy, Cl -6alkyl, Cl-6alkoxy, amino, NH(alkyl), N(alkyl)2;
R6 and R7 are independently selected from the group comprising hydrogen, CI -10 alkyl, - COR8, -CH20COR8, -CH20CONHR8R9, -COOR8, -CONR8R9, -S02R8, aryl, aralkyl;
R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl; n is 1 ,2, or 3. and salts, hydrates and stereoisomers thereof.
A general procedure involves the coupling reactions of acid with an amine or alcohol (R3X). In one method, an acid (A) is used as a starting material which can be activated by converting it to corresponding acid chloride using reagent such thionyl chloride or oxalyl chloride in a solvent such as DCM with or without a small amount of DMF at temperature ranging from room temperature to reflux and then by reaction of this acid chloride with a desired amine or alcohol (R3X)to arrive at other members of the series.
Another method involves the use of an acid coupling reagent is such as carbodiimide in an organic solvent such as DMF with or without an organic base such DMAP. Alternatively, acid can be activated by converting to corresponding ester using alcohol such as methanol first before reacting it with an amine or alcohol in a solvent such as benzene with or without a base such as sodium methoxide to arrive at other members of the series.
D. Methods of Use and Pharmaceutical Composition containing the Novel Entities of the Invention
The invention thus provides the use of the novel compounds as defined herein for use in human or veterinary medicine. The compounds of the present invention may be used in the treatment and prevention of diseases caused by mycobacteria such as tuberculosis. The said tuberculosis may be caused by mycobacterial species consisting of Mycobacterium tuberculosis, M. bovis, M africanum, M. canettior M. microti. Particularly, the compounds of the present invention are effective in inhibiting the growth of the M. tuberculosis. Tuberculosis as mentioned herein comprises active tuberculosis or latent tuberculosis. The active tuberculosis comprises drug sensitive, mono-drug resistant, multi-drug-resistant tuberculosis (MDR), extensively drug- resistant tuberculosis (XDR) or totally drug resistant tuberculosis.
In an aspect, the compounds of the present invention may be used in the treatment of tuberculosis including MDR, XDR and TDR tuberculosis.
In an aspect, the compounds of the present invention may be used either alone or in combination with cycloserine, amikacin, linezolid, ethambutol, rifampicin, isoniazid, ethionamide, moxyfloxacin, clarithromycin, PAS, clofazamine, streptomycin, capreomycin and kanamycin and DOTS ("Directly Observed Treatment, Short-course") therapy.
In another aspect, the compounds of the present invention may also be used prophylactically in preventing the occurrence of tuberculosis in healthcare providers, health workers, community members and the alike who are directly in contact with tuberculosis patients. The compounds of the present invention may be used for treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis as defined above. The compounds of the present invention are effective against tuberculosis and said tuberculosis includes drug- sensitive, mono-drug resistance, multi drug-resistant (MDR), extensively drug-resistance (XDR) and totally drug resistance (TDR) caused by a strain of Mycobacterium tuberculosis Mycobacterium strains. The compounds of the present invention may be used for the treatment of multi-drug-resistant (MDR), extensively drug-resistance (XDR) and totally drug resistance (TDR) tuberculosis caused by a strain Mycobacterium tuberculosis and for treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis as defined above by inhibition of GPR109A inhibition by an agent.
The compound for use as a pharmaceutical may be presented as a pharmaceutical composition. The invention therefore provides in a further aspect a pharmaceutical composition comprising the novel compounds of the invention along with pharmaceutically acceptable excipients/carriers thereof and optionally other therapeutic and/or prophylactic ingredients. The excipients/carriers must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. Suitably the pharmaceutical composition will be in an appropriate formulation.
The pharmaceutical formulations may be any formulation and include those suitable for oral, intranasal, or parenteral (including intramuscular and intravenous) administration. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
For these purposes the compounds of the present invention may be administered orally, topically, intranasally, , parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasteral injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, dogs, cats, etc. The compounds of the present invention are effective in the treatment of humans.
In an aspect, compound of the present invention may be administered in a dose ranging from 0.1 to 100 mg/kg body weight per day. The compounds of the present invention are useful for the prevention and treatment of tuberculosis and may be used as GPR109A inhibitors.
E. Experimental
The compounds of present invention may be prepared by the schemes as here below:
Synthetic Scheme 1:
Figure imgf000039_0001
Step 1 :
To a solution of OH (21.0 gm) in water (42.0 ml), ethanol (54.0 ml) and the compound [1] (25. Og, 1 19mmol) was added and the resulting solution was refluxed for 30 minutes and poured into a glass plate and left overnight at RT. The semisolid obtained was dissolved in water (400 ml) and washed with ethyl acetate. The pH of the aqueous layer was adjusted to acidic with 50% HCI, and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous Na2S04 and concentrated to give 2-hydroxy-2,2-diphenylacetic acid,(12.0 g, 45%). Analytical Data: [2] ESIMS: 229 [M++l]
Step 2
To a solution of the compound obtained in the above step (12g, 52.6mmol) in Methanol (100.0 ml) at 0°C, thionyl chloride (5.0 ml) was added and the resulting solution was refluxed for 4 hr. Ethanol was concentrated under vacuum and the residue was purified by column chromatography using 20% ethyl acetate in hexane to give ethyl 2-hydroxy-2,2- diphenylacetateas liquid (10.08g, 76%).Analytical Data: [3] ESIMS: 257 [M++l]
Step 3:
To a solution of [3](1.00 g, 5.23 mmol) in benzene (90 mL),sodium (1 10 mg) was added. After refluxing for 2.5 h, a solution of methylbenzilate (1.27 g, 5.23 mmol) was added and the reaction refluxed overnight. The benzene was evaporated in vacuo and the residue purified by flash chromatography (eluted first with 20% EtOAc/Hexane, then 5%MeOH/CH2Cl2) to give [1O04] as transparent liquid (981 mg,46%).Analytical Data:
[1004] ESIMS: 402[M++1]
Step 4:
To a stirred solution of [1004] (0. 5 g, 1.24mmol) in a mixture of ethyl acetate and methanol (1 ;1, 5 ml), was added a slurry of 10% Pd/C (0.02 g) at room temperature. Hydrogen balloon pressure was applied and the reaction mixture was stirred for 3hr at RT. Reaction was monitored using TLC. The reaction mass was filtered over celite and excess of solvent was removed under vacuum to afford light brown sticky material, which was further purified using silica gel column and 2% methanol in dichloromethane as eluent to afford [1003] as an off-white sticky material(0.22g, 57%).Analytical Data: [1003] ESIMS: 312 [M++l]
Step 5:
To a stirred solution of [1003] (0.12g, 0.38 mmol) in DMF, anhydrous K2C03 (0.05g, 0.41 mmol) was added at 0°C under nitrogen atmosphere. After an additional stirring for 15 minutes at same temperature, Methyl iodide (0.02 ml, 0.41 mmol) was added drop-wise. The reaction temperature was allowed to increase up to 25 °C and stirring was continued for 3 h. Consumption of [1003] was monitored by TLC. After complete consumption of [1003], water (50 ml) was added and organic layer was extracted with ethyl acetate (2x 50 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material which was further purified using silica gel column chromatography using 5% ethyl acetate/hexane as eluent to afford [1001] as white solid (0.08g, 65%,). Analytical Data: [1001] ESIMS: 326 [M++l].
Step 6:
To a stirred solution of [1003] (0.05g, 0.16 mmol) in DCM, triethylamine (0.03ml, 0.24 mmol) was added at 0°C under nitrogen atmosphere. After an additional stirring for 5 minutes at same temperature, Dimethylcarbamoyl chloride (0.02 ml, 0.24 mmol) was added drop- wise. The reaction temperature was allowed to increase up to 25°C and stirring was continued for 1 h. Consumption of [1003] was monitored by TLC. After complete consumption of
[1003], water (50 ml) was added and organic layer was extracted with ethyl acetate (2 x 25 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material which was washed further with DCM and pentane to afford [1006] (0.04g, 65%).Analytical Data:[1006]ESIMS: 385 [M++l].
Synthesis of [1010], [1012], [1008], [1013], [1018], [1007], [1009], [1014], [1019] and
[1023] were carried out by procedure described for [1004].
Synthesis of [1005], [1011] and [1015] were carried out by procedure described for [1006].
Synthetic Scheme 2:
Figure imgf000041_0001
[1024] [1025]
Step 1:
To a stirred solution of [5] (2.0g, 10.47mmol), vinyl acetate (10.0ml, lOO.Ommol) was added at room temperature. After an additional stirring for 5 minutes at same temperature, PS-IM (0.20g, 10%) was added. The reaction temperature was allowed to increase up to 40°C and stirring was continued for 16 h. Reaction mixture was passed through the bed of celite and evaporated to dryness which was further purified using silica gel column chromatography using 10% ethyl acetate/hexane as eluent to afford [6](0.9g, 45%)and [7] (0.8g, 40%) as transparent sticky material. Analytical Data: [6] ESIMS: 192 [M++1][7]ESIMS: 234 [M++l].
Step 2:
To a solution of [6] (0.45 g, 1.8mmol) in benzene (45 mL) was added sodium (0.03g, 1.6mmol). After refluxing for 2.5 h, a solution of ethyl benzilate (0.35 g, 1.8mmol) was added and the reaction refluxed overnight. The benzene was evaporated in vacuo and the residue purified by flash chromatography (eluted first with 20% EtOAc/Hexane, then 5%MeOH/CH2Cl2) to give [1024] as transparent liquid (0.35g,48%).
Analytical Data: [1024] ESIMS: 402[M++1]
Step 3:
To a solution of [7] (0.60g, 2.5mmol) in a mixture of THF/MeOH/H20 (9ml) was added Lithium hydroxide (0.20g, 5.0mmol). The reaction mixture was stirred at room temperature for 4h. TLC showed complete consumption of starting material. Reaction mixture was evaporated to dryness. Water was added and extracted with ethylacetate (2x50ml) to afford light transparent sticky material [8] (0.35g, 73%).Analytical Data: [8] ESIMS: 192[M++1] Step 4:
[1025] was synthesized as described in step 2.Analytical Data:[1025]ESIMS: 402[M++1] Synthesis of [1026] and [1027] were carried out by procedure described for [1024]
Synthetic Scheme 3:
Figure imgf000042_0001
[1020] [1016] Step 1:
To a stirred solution of [5] (l .Og, 5.2mmol) in DCM (20.0ml) was added TEA (1.9g, 15.2mmol) at room temperature. After an additional stirring for 5 minutes at same temperature, Mesyl chloride (0.55ml, 7.8mmol) was added. The reaction temperature was allowed to stirred at this temperature for 3h. TLC showed complete consumption of starting material. Water (100 ml) was added and organic layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material [9] which was used further without any purification (l.lg, 78%).Analytical Data: [9]ESIMS: 270 [M++l].
Step 2:
To a stirred solution of [9] (0.5g, 1.8 mmol) in DMF (10.0ml) was added sodium azide (0.46g, 7.2mmol) at room temperature. The temperature of reaction mixture was raised to 100°C and allowed to heat at this temperature for 2 hr. TLC showed complete consumption of starting material. Water (100 ml) was added and organic layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material [10] which was used further without any purification (0.3g, 77%). Analytical Data:[10] ESIMS: 217 [M++l].
Step 3:
To a stirred solution of [10] (0.3g, 1.3mmol) in THF (10.0ml) was added triphenylphosphine (0.5g, 1.9mmol) at room temperature. After an additional stirring for 5 minutes at same temperature, water (0.2ml, 9.1mmol) was added. The reaction temperature was allowed to reflux at 70°C for 2h. TLC showed complete consumption of starting material. Reaction mixture was evaporated and water (100 ml) was added and organic layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky which was subjected to column chromatography with 2% MeOH/DCM as eluent to afford light brown sticky material [11] (0.2g, 80%).Analytical Data: [11]ESIMS: 191 [M++l]
Step 4:
To a stirred solution of [12] (0.2g, 0.87mmol) in DMF (5.0ml) was added EDC (0.25g, l Jmmol), HOBT (0.17g, 1.3mmol) at room temperature. After an additional stirring for 5 minutes at same temperature, [ll](0'.18g, 0.91mmol) and NMM (0.37ml, 2.61mmol) was added. The reaction temperature was allowed to stirred at room temperature for overnight. TLC showed complete consumption of starting material. Water (100 ml) was added and organic layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky which was subjected to column chromatography with 1% MeOH/DCM as eluent to afford light brown solid material[13] (0.25g, 76%).Analytical Data: [13JESIMS: 400 [M++l]
Step 5:
To a stirred solution of [13] (0.25 g, 0.62mmol) in a mixture of ethyl acetate and methanol (1 ; 1, 5 ml), was added a slurry of 10% Pd/C (0.02 g) at room temperature. Hydrogen balloon pressure was applied and the reaction mixture was stirred for 3hr at RT. Reaction was monitored using TLC. The reaction mass was filtered over celite and excess of solvent was removed under vacuum to afford light brown sticky material, which was further purified using silica gel column and 2% methanol in dichloromethane as eluent to afford [1016] as off white sticky material(0.1 1 g, 57%).Analytical Data: [1016]ESIMS: 311 [IvT+1]
Step 6:
To a stirred solution of [1016] (0.1 Og, 0.32 mmol) in DMF, anhydrous K2C03 (0.06g, 0.48 mmol) was added at 0°C under nitrogen atmosphere. After an additional stirring for 15 minutes at same temperature, Methyl iodide (0.03 ml, 0.48 mmol) was added drop-wise. The reaction temperature was allowed to increase up to 25°C and stirring was continued for 3 h. Consumption of [1016] was monitored by TLC. After complete consumption of [1016], water (50 ml) was added and organic layer was extracted with ethyl acetate (2x 50 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material which was further purified using silica gel column chromatography using 10 % ethyl acetate/hexane as eluent to afford [1020] as white solid (0.05g, 50%,). Analytical Data: [1020]ESIMS: 325 [M++l]
Synthesis of [1017], [1021], [1022], [1028], [1029], [1030], [1031] and [1032] were carried out by procedure described for [1020] Synthetic Scheme 4:
Figure imgf000045_0001
Step 1:
To a stirred solution of [14] (0.50g, 4.34 mmol) in benzene (30ml), PTSA (0.74g, 4.34 mmol) was added at room temperature under nitrogen atmosphere. After an additional stirring for 15 minutes at same temperature, [15](0.65g, 4.34mmol) was added. The reaction temperature was allowed to increase up to 90°C and stirring was continued for 5 h. Consumption of [15] was monitored by TLC. After complete consumption of [15], water (50 ml) was added and organic layer was extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material which was further purified using silica gel column chromatography using 30 % ethyl acetate/hexane as eluent to afford mixture of [1037] and
[1038] which was further separated by prep-HPLC to afford [1037] (0.1 Og, 9% ) and [1038] (0.08g, 8%) as transparent sticky material. Analytical Data: [1037 andl038]ESIMS: 250 [M++l ].
Step 2:
To a stirred solution of [1037] (0.05g, 0.20 mmol) in Acetonitrile (2ml), methyl iodide (0.01ml, 0.20 mmol) was added at room temperature under nitrogen atmosphere. The reaction temperature was allowed to stirred at this temperature for overnight. After complete consumption of [1037], reaction mixture was evaporated to dryness to afford light yellow solid which was further purified by washing with Dichloromethane and ether to afford pure product [1065] (0.04g,51%). Analytical Data: [1065]ESIMS: 364 [M+].
Step 3: [1064] was synthesized similar to [1065] as described in step 2. Analytical Data:
[1064JESIMS: 364[M+] Synthesis of [1039], [1040], [1041], [1042], [1043], [1044], [1045], [1046], [1047], [1048],
[1049], [1050], [1051], [1052], [1055], [1057], [1058], [1059], [1053], [1054], [1063],
[1067], [1068], [1069], [1070], [1071], [1073], [1061], [1062], [1074], [1075], [1076],
[1077]and [1093] were carried out by procedure described for [1064] and [1065].
Synthetic Scheme 5:
Figure imgf000046_0001
Step 1:
To a stirred solution of [17] (0.08g, 0.42mmol) in DMF (5.0ml) was added EDC (0.12g, 0.63 mmol), HOBT (0.08g, 0.63mmol) at room temperature. After an additional stirring for 5 minutes at same temperature, [16](0.08g, 0.42mmol) and NMM (0.14ml, 2.3mmol) was added. The reaction temperature was allowed to stir at room temperature for overnight. TLC showed complete consumption of starting material. Water (100 ml) was added and organic layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky which was subjected to column chromatography with 1% MeOH/DCM as eluent to afford off white solid material[18] (0.1 lg, 68%). Analytical Data:
[18] ESIMS: 385 [M++l ].
Step 2:
To a stirred solution of [18] (0.1 l g, 0.28 mmol) in Acetonitrile (2ml), methyl iodide (0.02ml, 0.28 mmol) was added at room temperature under nitrogen atmosphere. The reaction temperature was allowed to stirred at this temperature for overnight. After complete consumption of [18], reaction mixture was evaporated to dryness to afford light yellow solid as a mixture of [1 1081] and [1 1082] which was further purified by prep-HPLC to afford
[1078] (0.03g, 20%) and [1079] (0.4g, 27%) as light yellow solid material. Analytical Data:
[1078 and 1079] ESIMS: 399 [M ]. Synthesis of [1080], [1081], [1082], [1083], [1084] and [1034] were carried out by procedure described for [1078] and [1079]
Synthetic Scheme 6:
Figure imgf000047_0001
Step 1:
To a stirred solution of [19] (0.80g, 4.81mmol) in DMF (5.0ml) was added EDC (1.40g, 7.2 mmol), HOBT (0.97g, 7.2mmol) at room temperature. After an additional stirring for 5 minutes at same temperature, [20](l . l lml, 5.30mmol) and NMM (1.6ml, 14.43mmol) was added. The reaction temperature was allowed to stirred at room temperature for overnight. TLC showed complete consumption of starting material. Water (100 ml) was added and organic layer was extracted with ethyl acetate (2 x 100 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light yellow powder which was triturated with pentane to afford off white solid material [21] (1.20g, 75%).Analytical Data: [21] ESIMS: 339 [M++l].
Step 2:
To a stirred solution of [21] (0.5 g, 1.4mmol) in methanol (10ml), was added a slurry of 10% Pd/C (0.05 g) at room temperature. Hydrogen balloon pressure was applied and the reaction mixture was stirred for 3hr at RT. Reaction was monitored using TLC. The reaction mass was filtered over celite and excess of solvent was removed under vacuum to afford off white powder [1085] (0.3 g, 86%).Analytical Data: [1085] ESIMS: 249 [M++l].
Step 3:
To a stirred solution of [1085 Hydrochloride] (0.05g, 0.20mmol) in DCM, triethylamine (0.07ml, 0.5mmol) was added at 0°C under nitrogen atmosphere. After an additional stirring for 5 minutes at same temperature, Ethyl chloroformate (0.02 ml, 0.22mmol) was added drop-wise. The reaction temperature was allowed to increase up to 25°C and stirring was continued for 1 h. Consumption of [1085] was monitored by TLC. After complete consumption of [1085], water (50 ml) was added and organic layer was extracted with ethyl acetate (2 x 25 ml). The combined organic layers were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated to afford light brown sticky material which was washed further with DCM and pentane to afford [1094] (0.03g, 64%).Analytical Data: [1094] ESIMS: 321 [M++l].
Synthesis of [1086], [1087], [1088], [1089], [1090], [1091], [1092], [1035] and [1036] were carried out by procedure described for [1085].
F. Biological Testing of the Compounds of Present Invention
Example 1: Inhibition of mycobacterium colony growth in macrophage by compounds of the present invention.
THP1 cells were seeded in a tissue culture plate in complete RPMI + 10% FCS and were allowed to differentiate to macrophages by addition of PMA with incubation at 37°C with 5% CO2. After 16-20 hr of PMA differentiation, cells were washed and replenished with complete RPMI. PMA-differentiated THP-1 cell were infected with tuberculosis bacteria H37Rv at an MOI of 10. Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged prior to incubation at 37°C with 5% C02. After 4hr, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing Amikacin to remove any remaining extra-cellular bacteria. Compound was added at concentrations of 5 to 500nM at 16hr and medium containing the appropriate dose of compound was refreshed every 24hrupto the 64hr time point. At the end of the assay at 90hr, cells were lysed with lysis buffer (7H9+ .06% SDS) and the residual bacterial loads determined as CFU counts. The results are graphically depicted in Table 2 which demonstrates that growth of Mycobacterial colony stood inhibited upon use of these compounds. Table 2: Screening of compounds for H37Rv% inhibition at lOOnM and 500nM
Compound No. H37Rv % Inhibition at 500 nM
1001 73
1002 NT
1003 22
1004 33
1005 55
1006 66
1007 46
1008 42
1009 46
1010 46
101 1 51
1012 51
1013 55
1014 77
1015 73
1016 65
1017 75
1018 66
1019 60
1020 64
1021 74
1022 75
1023 50
1024 72
1025 79
1026 71
1027 85
1028 77
1029 61
1030 52 1031 74
1032 72
1033 78
1034 64
1035 62
1036 58
1037 40
1038 56
1039 61
1040 79
1041 71
1042 73
1043 72
1044 65
1045 66
1046 56
1047 68
1048 79
1049 56
1050 42
1051 59
1052 73
1053 78
1054 74.
1055 52
1056 78
1057 76
1058 55
1059 74
1060 78
1061 NT
1062 NT
1063 NT 1064 NT
1065 NT
1066 NT
1067 NT
1068 NT
1069 NT
1070 NT
1071 NT
1072 NT
1073 NT
1074 24
1075 46
1076 50
1077 52
1085 93
NT= Not Tested
Example 3: In vitro infection of human PBMC derived macrophages, compound addition and cfu determination.
Heparinised human blood diluted 1 : 1 with RPMI 1640 was layered onto equal volume of Ficoll-Paque followed by centrifugation at 1600 rpm for 30 min. The PBMC layer formed at the interface was collected carefully and washed twice with RPMI. The cells were diluted in RMPI medium (without serum) to a concentration 2 x l06/ml and 10 ml of diluted cells were put into a 75-cm2 tissue culture flask, and incubated for 2 hrs in a humidified 37°C incubator. The non-adherent cells were removed by aspiration, followed by two washes with RPMI. Complete media (with 10% FCS) was added and the cells were allowed to spontaneously differentiate into macrophages for 4 days in a humidified 37°C, 5% C02 incubator. Bacteria were grown in Middlebrooke 7H9 broth supplemented with 10% ADC, 0.4% Glycerol and 0.05% Tween-80 until the mid-log phase. The bacteria were then harvested, washed with RPMI and re-suspended in the same media. The suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments. Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to 100 X 106 bacteria).
Human PBMC derived macrophages were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5% C02. After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200μg/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment. Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i. At 90h post infection, the cells were lysed in 50 μΐ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 μΐ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently flow in parallel tracks along the agar surface. The plates were then allowed to dry and subsequently incubated in a humidified incubator at 37°C. Colonies were counted on the 14th day and converted into cfu/well. The effect of one of the compounds of the present invention in reducing mycobacterial growth in human PBMC derived macrophages is shown as means of illustration at Table 3.
Table 3: Demonstration of reduction of colony count on use of the compound 1085
Figure imgf000052_0001
Example 4: In vitro infection of THP-1 macrophages, compound addition and cfu determination.
The human monocyte/ macrophage cell line THP-1 was cultured in RPMI 1640 supplemented with 10% FCS and were maintained between 2 and 10 X 105 cells per ml at 37°C in a humidified, 5% C02 atmosphere. Before infection, cells were plated in 96 well plates at 1 X 104 cells per well and differentiated with PMA (30 ng/ml) for a period of 48 hrs. Bacteria were grown in Middlebrooke 7H9 broth supplemented with 10% ADC, 0.4% Glycerol and 0.05% Tween 80 until the mid-log phase. The bacteria were then harvested, washed with RPMI and re-suspended in the same media. The suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments. Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to ~ 100 X 106 bacteria).
PMA-differentiated THP-1 cells were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5%C02. After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200μg/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment. Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i. At 90h post infection, the cells were lysed in 50 μΐ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 μΐ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently How in parallel tracks along the agar surface. The plates were then allowed to dry and subsequently incubated in a humidified incubator at 37°C. Colonies were counted on the 14th day and converted into cfu/well. The results are represented at Figure 1. From Figure 1, it may be inferred that compounds of the present invention produces dose dependent reduction in mycobacterial cfu's in MYC 431 infected macrophages.
Example 5: Determination of the effect of the compounds of the present invention on lipid bodies.
THP-1 cells were seeded onto #1 thickness, 12 mm diameter glass cover-slips in 24-well tissue culture plates at a density of 0.3x106 cells per cover slip. These cells were then infected M. tb (H37Rv) at a MOI of 10 and incubated for 4h at 370 C in 5% C02. Extracellular bacteria were removed by washing and subsequently by supplementing the medium with 200 μg/ml amikacin for 2h. SPR1 13 was added in increasing concentrations immediately after the amikacin treatment, and the medium containing the appropriate inhibitor was replenished at 16h and 40h post infection. At 48hrs post infection cells were fixed with 3.7% para-formaldehyde and washed with PBS. HCS LipidTox Red neutral lipid stain, diluted 1 : 1000 in PBS was added to the cells for 30 min. The cell nuclei were stained using 300nM DAPI solution (in H20) for 5 min and then washed. Stained cells were observed with a Nikon EclipseTi-E laser scanning confocal microscope equipped with 60X/1.4NA Plan Apochromat DIC objective lens. DAPI and Lipid Tox were excited at 408 nm and 543 nm with a blue diode and a Helium-Neon laser respectively. The emissions were recorded through emission filters set at 450 and 605/75 nm. Images were acquired with a scanning mode format of 512 x 512 pixels. The transmission and detector gains were set to achieve best signal to noise ratios and the laser powers were tuned to limit bleaching fluorescence. All images were quantified using Image-Pro Plus version 6.0, a commercially available software package from Media Cybernetics. The results are represented herebelow at Figure 2. Figure 2 shows dose dependent reduction in cellular lipid bodies in the presence of the compounds of the present invention.
Example 6: Effect of compounds against different mycobacterial strains.
THP-1 cells independently infected with r M.tb strains [JAL2287, JAL2261 , XDR]. Addition of the media containing compound was performed at 16 hr and the medium containing the appropriate dose of compound was refreshed every 24 hr up to the 64 hr time point. At the end of the total culture period of 90 hr, cells were lysed and CFUs were determined and results are as shown graphically in Figure 3. The cellular Potency of compound 1085 was measured in MTB infected THP1 and EC50 of H37Rv was 0.5nM and MYC431 and JAL2287 were 0.1 nM. The graph shows that compound inhibited all the mycobacterial strains at concentration of 0.01 to 500nM.
Example 7: Effect of compounds on c-AMP levels.
THP-1 macrophages were incubated with compd. 1085 at the indicated concentrations for 30 min, following which 3-hydroxybutyric acid. (3HBA, lOuM), a GPR109A agonist, was added to cells for 90 min. In the absence of compound 1085, 3HBA reduces intracellular cAMP levels while compound 1085 inhibits the activity in a dose dependent manner. The results are represented at Figure 4.
Example 8: Co-localization of M. tuberculosis with degradative vesicles: acidified lysosomes and autophagosomes in the presence of compound 1085
THP-1 cells were seeded onto glass cover-slips in 24-well tissue culture plates at a density of 0.3x 106 cells per cover slip. These cells were then infected GFP- tagged M. tb (H37Rv-GFP) at a MOI of 10 and incubated for 4h at 37° C in 5% C02. Extracellular bacteria were removed by washing and subsequently by supplementing the medium with 200 μg/ml Amikacin for 2hr. compound 1085 was added at 100 nM concentration immediately after the amikacin treatment, and the medium containing the compound was replenished at 16h and 40h post infection. At 48h cells were incubated with ΙΟΟηΜ of the acidotropic dye for 60 min followed by fixation of cells with 3.7% para- formaldehyde for 20 min, and washed. The dye stained cells were permeabilized with 0.2%(v/v) Triton X-100 for 20 min, washed with PBS and blocking buffer 3% (w/v)BSAwas added for 60 min. The cells were washed and LC3B rabbit Ab (Cell Signaling Technology), at a 1 :200 dilution, was added for 60 min at room temperature. Cells were washed with PBST (once) and PBS (twice). Alexa Fluor 405 goat anti-rabbit Ab at 1 :200 dilution was added for 45 min at room temperature. Cells were washed with PBST (once) and PBS (twice). The coverslips were mounted on slides with an antifade reagent. Stained cells were observed with a laser scanning confocal microscope. GFP and dyes were excited at 488 nm, 408 nm and 543 nm with an argon ion, blue diode and a Helium-Neon laser respectively. The emissions were recorded through emission filters set at 515/30; 450 and 605/75 nm. Serial confocal sections (0.5 μιη thick) within a z-stack spanning a total thickness of 10 μηι were taken in individual channels green, blue and red using the motor drive focusing system. Images were acquired with a scanning mode format of 512 x 512 pixels. The transmission and detector gains were set to achieve best signal to noise ratios and the laser powers were tuned to limit bleaching fluorescence. All images were quantified. The merged confocal images were deconvolved and subjected to co-localization analysis to determine the "Overlap Coefficient" as previously described (Manders et al, 1993). The results are presented at Figures 5a and 5b. Autophagosomes and acidified lysosomes are degradative vesicles that function in maintaining cellular homeostasis and are also an important component of the antimicrobial responses mounted by a macrophage to clear off intracellular infection. M. Tuberculosis modulates both these degradative pathways in order to ensure its continued survival within the macrophage. Interventions which lead to activation of these pathways in infected macrophages will lead to targeted killing of intracellular M. Tuberculosis and thus reduce mycobacterial load. The significance of the experiments done with compound 1085 is that treatment of infected macrophages with this compound leads to an increased co localization of mycobacteria with these degradative vesicles which is reflected by the increased value of the co localization coefficient (higher value of co localization coefficient indicates a higher percentage of bacteria present inside these degradative vesicles). The bacteria present inside these vesicles upon compound 1085 treatment are thus primed to be subsequently killed which in turn is reflected in the lower in vitro cfu's obtained with compound 1085.
Example 9: GPR109A specific effect of compound no. 1085 on cellular lipid bodies
THP-1 cells were seeded onto glass cover-slips in 24-well tissue culture plates at a density of 0.3xl 06 cells per cover slip. Ligand for GPR109A, 3-HB (10 uM) was added to the cells and in parallel sets. Compd. 1085 was added in increasing concentrations. At 48h post 3HB addition cells were fixed with 3.7% para-formaldehyde and washed with PBS. HCS LipidTox Red neutral lipid stain, diluted 1 : 1000 in PBS was added to the cells for 30 min. The cell nuclei were stained using 300nM DAPI solution (in H20) for 5 min and then washed. Stained cells were observed with a laser scanning confocal microscope equipped with Apochromat DIC objective lens. DAPI and Lipid Tox were excited at 408 nra and 543 nm with a blue diode and a Helium-Neon laser respectively. The emissions were recorded through emission filters set at 450 and 605/75 nm. Images were acquired with a scanning mode format of 512 x 512 pixels. The transmission and detector gains were set to achieve best signal to noise ratios and the laser powers were tuned to limit bleaching fluorescence. All images were quantified and the results are graphically depicted in Figure 6 which demonstrates that significant effect on average fluorescent intensity was observed in presence of compound 1085 representing decrease in the cellular lipid body.
Example 10: Effect of compound 1085 on intracellular mycobacterial load in THP-1 macrophages infected individually with 8 different strains of M. tuberculosis
The human monocyte/ macrophage cell line THP-1 was cultured in RPMI 1640 supplemented with 10% FCS and were maintained between 2 and 10 X 105 cells per ml at 37°C in a humidified, 5% C02 atmosphere. Before infection, cells were plated in 96 well plates at 1 X 104 cells per well and differentiated with PMA (30 ng/ml) for a period of 48 hrs. Bacteria were grown in Middlebrooke 7H9 broth supplemented with 10% ADC (Becton Dickinson), 0.4% Glycerol and 0.05% Tween 80 until the mid-log phase. The bacteria were then harvested, washed with RPMI and re-suspended in the same media. The suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments. Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to ~ 100 X 106 bacteria).
PMA-differentiated THP-1 cells were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5% C02. After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200μg/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment. Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i. At 90hr post infection, the cells were lysed in 50 μΐ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 μΐ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently flow in parallel tracks along the agar surface. The plates were then allowed to dry and subsequently incubated in a humidified incubator at 37°C. Colonies were counted on the 14th day and converted into cm/well. The results are graphically depicted in Figure 7 representing steady decrease in mycobacteria] load with increase in concentration of compound 1085 for all 8 strains of M. tuberculosis.
Example 11: Effect of combinations of compound 1085 with known anti-mycobacterial antibiotics on intracellular mycobacterial load in THP-1 macrophages infected with M. tuberculosis H37Rv.
The human monocyte/ macrophage cell line THP-1 was cultured in RPMI 1640 (Gibco Laboratories) supplemented with 10% FCS (Hyclone) and were maintained between 2 and 10 X 105 cells per ml at 37°C in a humidified, 5% C02 atmosphere. Before infection, cells were plated in 96 well plates at 1 X 104 cells per well and differentiated with PMA (30 ng/ml) for a period of 48 hrs. Bacteria were grown in Middlebrooke 7H9 broth (Difco) supplemented with 10% ADC (Becton Dickinson), 0.4% Glycerol and 0.05% Tween 80 until the mid-log phase. The bacteria were then harvested, washed with RPMI and resuspended in the same media. The suspension was dispersed by aspiration twelve times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. This suspension was allowed to stand for 5 min. The upper half of the suspension was then used for the experiments. Bacteria were quantified by measuring the absorbance at a wavelength 600nm (0.6 O.D. corresponds to ~ 100 X 106 bacteria).
PMA-differentiated THP-1 cells were infected with tuberculosis bacteria at a MOI of 10 (i.e., 10 bacteria per cell). Infection was performed in antibiotic free RPMI supplemented with 10% FCS. After adding bacteria, culture plates were centrifuged at 700 rpm for 5 min prior to incubation at 37°C with 5% C02. After 4h, infected cells were washed twice with warm RPMI and replenished with complete RPMI containing 200μg/mL amikacin for 2h to remove any remaining extra-cellular bacteria. Subsequently, cells were washed and then maintained in complete RPMI for the rest of the experiment. Inhibitor addition was performed at 16hrs post infection (p.i) and the medium containing the appropriate dose of inhibitor was replenished at 40hrs and 64hrs p.i. At 90h post infection, the cells were lysed in 50 μΐ of 0.06% SDS for 10 min at room temperature. Lysate dilutions of 1 : 10 were plated in duplicate sets on 7H 1 1 agar plates. Square plates (12 X 12 cm) were used for the plating, by the track dilution method in which 10 μΐ of each dilution was spotted on one side of square plate. The plate was then tipped onto its side (at a 45°- 90° angle), and the spots were allowed to gently flow in parallel tracks along the agar surface. The plates were then allowed to dry and subsequently incubated in a humidified incubator at 37°C. Colonies were counted on the 14th day and converted into cfu/well. The Figure 8 shows that the compound 1085 does not negatively affect the activities of the known anti TB antibiotics and in some cases there might be additive/synergistic effects.
Example 12: Compound 1085 treatment in mice (oral dosing)
Groups of naive mice (female BALB/c mice 4-6 wk of age at 5/group) were infected with MDR- M. tb (JAL2287) through the aerosol route by delivering between 150-200 bacteria per lung during 30 min of exposure. One group of mice was sacrificed 24 h later and lung homogenates were plated onto 7H1 1 agar plates for confirming infection. At fifteen days post infection, compoundl 085 treatment was initiated by delivering the compound orally. Individual groups of mice were treated at the following doses: 100, 30, and 10 mg/kg body weight/ day (1085 was solubilized in PEG400). At fourteen days following treatment, mice were sacrificed and lung and spleen enriched using a homogenizer. An aliquot (100 μΐ) of the serially diluted homogenate (10-2 & 10-3) was plated onto 7H1 1 agar plates for determining the mycobacterial load. The cfu's were counted at 18 days post plating on the agar plates. The results of pharmacokinetic parameters via intraperitoneal route are represented graphically at Figures 9a and 9b. The pharmacokinetic parameter via oral route is presented herebelow at Table 3 and 4. From the figures and tables it may be inferred that compounds of the present invention, illustrated by an exemplary compound 1085 were found to be effective at all experimental doses. The pharmacokinetic (PK) data of compound 1085 is represented in Table 5 and 6 demonstrating that compound 1085 has very good bioavailability in both mouse and dog.
Table 3: Reduction of CFU in lung (Oral Dosing)
Figure imgf000059_0001
Table 4: Reduction of CFU in spleen (Oral Dosing)
Compd. 1085 (mg/kg/day) CFU/spleen (xlO3) % Reduction p value
0 11.8
10 0.4 96.6 0.0001
30 0.2 98.3 0.0001
100 0.2 98.3 0.0001 Table 5: P data of Compound 1085 in Mouse
Figure imgf000060_0001
Dog Bioavailability: 57%
Example 13: Compound 1085 + ATT combination treatment in mice (oral dosing)
Groups of naive mice (female BALB/c mice 4-6 wk of age at 5/group) were infected with drug susceptible M. tb (H37Rv) through the aerosol route by delivering between 150-200 bacteria per lung during 30 min of exposure. One group of mice was sacrificed 24 h later and lung homogenates were plated onto 7H1 1 agar plates for confirming infection. At fifteen days post infection, oral drug treatment was initiated with a single dose per day. One group received Anti-TB therapy, ATT (Isoniazid: 1.5mg/kg + Rifampicin: lmg/kg + Pyrazinamide: 1 .5mg/kg + Ethambutol : 1.5mg/kg), one group received compd. 1085 (l Omg/kg) and a parallel group received a combination of comd. 1085 and ATT (Isoniazid: 1.5mg/kg + Rifampicin: lmg/kg + Pyrazinamide: 1.5mg/kg + Ethambutol : 1.5mg/kg + Compound 1085: l Omg/kg). At 1 week, 2 weeks and 4 weeks post treatment mice were sacrificed along with a control (mocka treated) group and lungs enriched using a homogenizer. An aliquot (100 μΐ) of the serially diluted homogenate (10" & 10" ) was plated onto 7H1 1 agar plates for determining the mycobacterial load. The CFU's were counted at 18 days post plating on the agar plates. Combination treatment of compd. 1085 with ATT demonstrates significant reduction in lung CFU as depicted in Figure 10. The data is represented in below Table7.
Table 7: Combination treatment of compd. 1085 with ATT
GROUP CFU/Lung (xlO5) SD
Untreated 19.54 2.09
Compd. 1085 (lOmg/kg) 4.76 0.76
ATT
• Isoniazid: 1.5mg/kg
• Rifampicin: lmg/kg 1.76 0.42
• Pyrazinamide: 1.5mg/kg
• Ethambutol: 1.5mg/kg
Compd. 1085 + ATT 0.36 0.1 1

Claims

Claims:
1. A compound of structural Formula (1), including its salts, hydrates and stereoisomers:
Figure imgf000062_0001
Formula 1 wherein
X is selected from O, NH or N(alkyl);
Ri and R2are independently selected from hydrogen, deuterium, hydroxyl, CMO straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci-6alkoxy,aryl, amino, NH(alkyl), N(alkyl)2 OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group comprising O, N or S; or Ri and R2 may combined to form an aryl or a heteroaryl ring containing 1 -3 heteroatoms selected from the group comprising O, N or S;
R3isselected from hydrogen, hydroxyl, Ci- straight chain or branched chain alkyl, 3-7 membered cycloalkyl,Ci-6alkoxy, aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
Figure imgf000062_0002
X may in conjunction with Reform a5-7 membered heterocyclic ring comprisingl-3 heteroatoms selected from group comprising N, O or S. The heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH-aralkyl;
R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, C]-6 alkoxy, amino, NH(alkyl), N(alkyl)2, -COORg, CONR8R9;
R5 is hydrogen, hydroxy, Ci^alkyl, Ci^alkoxy, amino, NH(alkyl), N(alkyl)2;
R6 and R7 are in dependently selected from the group comprising hydrogen, CJ.JO alkyl, - COR8, -CH2OCOR8, -CH2OCONHR8R9, -COOR8, -CONR8R9, -S02R8, aryl, aralkyl;
R8 and R9areindependently selected from the group comprising hydrogen, or Ci.6 straight chain or branched chain alkyl; n is 1 ,2, or 3.
2. The compound of structural Formula (1) as claimed in claim 1 , including its salts, hydrates and stereoisomers:
Figure imgf000063_0001
Formula
wherein
X is NH;
Ri and R2 are independently selected from hydrogen, hydroxyl, Ci.io alkyl,Ci-6alkoxy; R3 is selected from substituted aromatic or non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
Figure imgf000064_0001
R4 is selected from hydrogen, deuterium,halogen,Ci-6 straight chain or branched chain alkyl, Ci.6 alkoxy, amino, NH(alkyl), N(alkyl)2; 6 and R7 are independently selected from hydrogen, CMO alkyl, -COR8, -CH2OCOR8, - CH2OCONHR8R9, -COOR8, -CONR8R , -S02R8, phenyl, benzyl;
R8 and R9are independently selected from hydrogen or Cj_6 straight chain or branched chain alkyl; n is 1 ,2 or 3.
3. A compounds of Formula (1), including its salts, hydrates and stereoisomer' s thereof wherein said compound is selected from the group comprising:
i. 1 -Methylpiperidin-3-yl-2-hydroxy-2,2-diphenylacetate;
ii. 3-(2-Hydroxy-2,2-diphenylacetoxy)-l-(((isopropylcarbamoyl)oxy)methyl)-l- methylpiperidin-1 -ium;
iii. Piperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
iv. l -Benzylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
v. 1 -(Methylsulfonyl)piperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
vi. l-(Dimethylcarbamoyl) piperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
vii. 1 -Benzylpiperidin-4-yl 2-hydroxy-2,2-diphenylacetate;
viii. 3-(2-Hydroxy-2,2-diphenylacetoxy)-l -methylquinuclidin-l -ium;
ix. l -Benzylpyrrolidin-3-yl 2-hydroxy-2,2-diphenylacetate;
x. l-Ethylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xi. 1 -(Isopropylcarbamoyl) piperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xii. l-Propylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xiii. 1 -Methylpiperidin-4-yl 2-hydroxy-2,2-diphenylacetate;
xiv. l-Benzylazetidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xv. l-Acetylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate; xvi. 2-Hydroxy-2,2-diphenyl-N-(piperidin-3-yl)acetamide;
xvii. N-( 1 -Benzylpiperidin-4-yl)-2-hydroxy-2,2-diphenylacetamide; xviii. l-Methylpyrrolidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xix. Quinuclidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xx. 2-Hydroxy-N-(l-methylpiperidin-3-yl)-2,2-diphenylacetamide; xxi. N-(l-Benzylpiperidin-4-yl)-2-hydroxy-2,2-diphenylacetamide; xxii. N-(l -Benzylazetidin-3-yl)-2-hydroxy-2,2-diphenylacetamide;
xxiii. Azetidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxiv. (S)-l -Benzylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxv. (R)-l -Benzylpiperidin-3 -yl 2-hydroxy-2,2-diphenylacetate;
xxvi. (S)-l-Methylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxvii. (R)-l -Methylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate;
xxviii . (R)-N-( 1 -Benzylpiperidin-3 -yl)-2-hydroxy-2,2-diphenylacetamide; xxix. (R)-N-( 1 -Benzylpiperidin-3-yl)-2-hydroxy-2,2-diphenylacetamide; xxx. 2-Hydroxy-2,2-diphenyl-N-(piperidin-4-yl)acetamide;
xxxi . (S)-2-Hydroxy-N-( 1 -methylpiperidin-3 -yl)-2,2-dipheny lacetamide ; xxxii. (R)-2-Hydroxy-N-(l-methylpiperidin-3-yl)-2,2-diphenylacetamide; xxxiii. l-Benzylazetidin-3-yl 2-hydroxy-2-phenylpropanoate;
xxxiv. (R)-N-(l -Benzylpiperidin-3 -yl)-2,2-diphenylacetamide;
xxxv. N-((S)- 1 -Benzylpiperidin-3-yl)-2-hydroxy-2-phenylacetamide; xxxvi . N-((R)- 1 -Benzylpiperidin-3 -yl)-2-hydroxy-2-pheny Ipropanamide ; xxxvii. (R)-(R)-1 -Methylpiperidin-3 -yl 2-hydroxy-2-phenylacetate;
xxxviii . (R)-(S)- 1 -Methylpiperidin-3 -yl 2-hydroxy-2-phenylacetate;
xxxix. (S)-(R)-l -Methylpiperidin-3-yl 2-hydroxy-2-phenylacetate;
xl. (S)-(S)-l -Methylpiperidin-3-yl 2-hydroxy-2-phenylacetate;
xli. (R)- 1 -Methylpiperidin-4-yl 2-hydroxy-2-phenylacetate;
xlii. (S)-2-Hydroxy-N-(l-methylpiperidin-4-yl)-2-phenylacetamide; xliii . (R)-2-Hydroxy-N-( 1 -methylpiperidin-4-yl)-2-phenylacetamide ; xliv. (R)-2-Hydroxy-N-((R)-l -methylpiperidin-3 -yl)-2-phenylacetamide; xlv. (R)-2-Hydroxy-N-((S)-l -methylpiperidin-3-yl)-2-phenylacetamide; xlvi. (S)-2-Hydroxy-2-phenyl-N-(pyridin-3-yl)acetamide;
xlvii . (S)- 1 -Methylpiperidin-4-yl 2-hydroxy-2-phenylacetate;
xlviii. (S)-l-Benzylazetidin-3-yl 2-hydroxy-2-phenylacetate;
xlix. (S)-(R)-Quinuclidin-3-yl 2-hydroxy-2-phenylacetate;
1. (S)-(S)-Quinuclidin-3-yl 2-hydroxy-2-phenylacetate;
li. (R)-N-(l -Benzylpiperidin-4-yl)-2-hydroxy-2-phenylacetamide;
Hi. (S)-N-( 1 -Benzylpiperidin-4-yl)-2-hydroxy-2-phenylacetamide;
liii . (R)-3 -((R)-2-Hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
liv. (S)-3 -((R)-2-Hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lv. (R)-2-Hydroxy-2-phenyl-N-(pyridin-3-yl)acetamide;
lvi. (R)-(S)-l-Methylpiperidin-3-yl 2-acetoxy-2-phenylacetate;
lvii. (R)-(R)- 1 -Methylpyrrolidin-3-yl 2-hydroxy-2-phenylacetate;
lviii. (R)-(S)- 1 -Methylpyrrolidin-3-yl 2-hydroxy-2-phenylacetate;
lix. (S)-(R)-l-Methylpiperidin-3-yl 2-methoxy-2-phenylacetate;
lx. 2-Methoxy-2-phenylacetic acid;
lxi. (R)-2-Hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
lxii. (R)-Piperidin-4-yl 2-hydroxy-2-phenylacetate;
lxiii. (R)-3-(2-Hydroxy-2,2-diphenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxiv. (R)-3-(2-Hydroxy-2,2-diphenylacetoxy)- 1 ,1 -dimethylpiperidin- 1 -ium;
lxv. (R)-3 -((R)-2-Hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxvi. (R)-3 -((R)-2-Hydroxy-2-phenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxvii. (S)-(R)-l-Methylpiperidin-3-yl 2-methoxy-2-phenylacetate;
lxviii. (S)-(S)-l-Methylpiperidin-3-yl 2-methoxy-2-phenylacetate;
lxix. (S)-2-Hydroxy-N-((R)-l-methylpiperidin-3-yl)-2-phenylacetamide;
lxx. (S)-2-Hydroxy-N-((S)- 1 -methylpiperidin-3-yl)-2-phenylacetamide;
lxxi. 3 -(2,2-Diphenylacetamido)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxxii. (2S)-l -Benzyl-2-((2,2-diphenylacetamido)methyl)-l-methylpyrrolidin-l-ium; lxxiii. 3 -(2-Hydroxy-2,2-diphenylacetamido)- 1 , 1 -dimethylpiperidin- 1 -ium;
lxxiv. (R)-2-Methoxy-l-((S)-3-methylmorpholino)-2-phenylethanone;
lxxv. (R)-2-Methoxy- 1 -((R)-3-methylmorpholino)-2-phenylethanone;
lxxvi. (R)-l-((2R,3S)-2,3-Dimethylmorpholino) -2-methoxy-2-phenylethanone; lxxvii. (S)-2-Methoxy-l-((S)-3-methylmorpholino)-2-phenylethanone;
lxxviii. ( 1 R,3 R)- 1 -Benzyl-3 -(2,2-diphenylacetamido)- 1 -methylpiperidin- 1 -ium; lxxix. ( 1 S,3 R)- 1 -Benzyl-3 -(2,2-diphenylacetamido)- 1 -methylpiperidin- 1 -ium; lxxx. ( 1 S,3 R)- 1 -Benzyl-3 -(2,2-diphenylacetamido)- 1 -methylpiperidin- 1 -ium; lxxxi. ( 1 R,3R)-1 -Benzyl-3-(2,2-diphenylacetamido)- 1 -methylpiperidin- 1 -ium; lxxxii . 1 -(3 -(Benzylamino)piperidin- 1 -yl)-2,2-diphenylethanone;
lxxxiii. N-(( 1 -Benzylpyrrolidin-2-yl)methyl)-2,2-diphenylacetamide; lxxxiv. 1 -Benzyl-2-((2,2-diphenylacetamido)methyl)- 1 -methylpyrrolidin- 1 -ium;
lxxxv. (R)-2-Methoxy-2-phenyl-N-(piperidin-4-yl)acetamide;
lxxxvi. 2-Hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
lxxxvii. (S)-2-Hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
lxxxviii. (S)-2-Methoxy-2-phenyl-N-(piperidin-4-yl)acetamide;
lxxxix . 2-Hydroxy-2-pheny l-N-(piperidin-4-yl)propanamide;
xc. 2-(3-Bromo-2,6-difluorophenyl)-2-hydroxy-N-(piperidin-4-yl)acetamide;
xci. (R)-2-Methoxy-N-methyl-2-phenyl-N-(piperidin-4-yl)acetamide;
xcii. (R)-N-(l -Benzylpiperidin-4-yl)-2-methoxy-N-methyl-2-phenylacetamide;
xciii. (S)-l-Benzylpiperidin-4-yl 2-methoxy-2-phenylacetate;
xciv. (R)-Ethyl 4-(2-methoxy-2-phenylacetamido)piperidine- 1 -carboxylate;
A compounds having Formula (1), including its salts, hydrates and stereoisomer' s wherein said compound is selected from the group comprising:
i. (R)-2-Methoxy-2-phenyl-N-(piperidin-4-yl)acetamide;
ii. 2-Hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
iii . (S)-2-Hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
iv. (S)-2-Methoxy-2-phenyl-N-(piperidin-4-yl)acetamide;
v. 2-Hydroxy-2-phenyl-N-(piperidin-4-yl)propanamide;
vi. 2-(3-Bromo-2,6-difluorophenyl)-2-hydroxy-N-(piperidin-4-yl)acetamide;
(R)-2-Hydroxy-2-phenyl-N-(piperidin-4-yl)acetamide;
vii . (R)-3-(2-Hydroxy-2,2-diphenylacetoxy)- 1 , 1 -dimethylpiperidin- 1 -ium;
5. A process for preparing the compounds as claimed in claim 1 having Formula (1), comprising:
Figure imgf000067_0001
coupling of compound A with that of compound B in presence of coupling agent (i) and an organic solvent; wherein:
X is selected from O, NH or N(alkyl);
Ri and R2are independently selected from hydrogen, deuterium, hydroxyl, Cj.io straight chain or branched chain alkyl, 3-7 membered cycloalkyl, Ci^alkoxy, aryl, amino, NH(alkyl), N(alkyl)2 COR5, heteroaryl containing 1 -3 heteroatoms selected from the group comprising O, N or S; or R] and R2 may combined to form an aryl or a heteroaryl ring containing 1 -3 heteroatoms selected from the group comprising O, N or S;
R3 is selected from hydrogen, hydroxyl, C i-6 straight chain or branched chain alkyl, 3-7 membered cycloalkyl,C i-6alkoxy, aryl, aromatic or non-aromatic heterocyclic ring or fused heterocyclic rings elected from:
Figure imgf000068_0001
X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group comprising N, O or S. The heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH-aralkyl;
R4 is selected from a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, C I -6 alkoxy, amino, NH(alkyl), N(alkyl)2, -COOR8, CONR8R9;
R5 is hydrogen, hydroxy, Cl-6alkyl, Cl -6alkoxy, amino, NH(alkyl), N(alkyl)2;
R6 and R7 are independently selected from the group comprising hydrogen, C l-10 alkyl, -COR8, -CH20COR8, -CH20CONHR8R9, -COOR8, -CONR8R9, -S02R8, aryl, aralkyl; R8 and R9 are independently selected from the group comprising hydrogen, or CI -6 straight chain or branched chain alkyl; n is 1 ,2, or 3. and salts, hydrates and stereoisomers thereof;
6. The compounds as claimed in claim 1 to 4 for use in treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis.
7. The compounds as claimed in claim 1 when combined with cycloserine, amikacin, linezolid, ethambutol, rifampicin, isoniazid, ethionamide, moxyfloxacin, clarithromycin, PAS, clofazamine, streptomycin, capreomycin and kanamycin and other anti-tubercular agents for treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis.
8. The pharmaceutical composition comprising a compound of formula (1) as claimed in Claim 1 to 4 along with pharmaceutically acceptable excipients.
9. The pharmaceutical composition as claimed in Claim 8, further to be used either alone or in combination with atleast one additional pharmaceutical compound for treatment of the infection caused by resistant and non-resistant Mycobacterium tuberculosis as defined above.
10. The pharmaceutical composition as claimed in Claim 8, wherein the said pharmaceutical compound is selected from the group consisting of cycloserine, amikacin, linezolid, ethambutol, rifampicin, isoniazid, ethionamide, moxyfloxacin, clarithromycin, PAS, clofazamine, streptomycin, capreomycin and kanamycin.
1 1. The use as claimed in claim 1 1 , wherein the said tuberculosis includes drug-sensitive, mono-drug resistance, multi drug-resistant (MDR), extensively drug-resistance (XDR) and totally drug resistance (TDR) caused by a strain of Mycobacterium tuberculosis
12. The use as claimed in claim 1 1, wherein a compound of formula (1) to be used for the treatment of multi-drug-resistant (MDR), extensively drug-resistance (XDR) and totally drug resistance (TDR) tuberculosis caused by a strain Mycobacterium tuberculosis
13. The use as claimed in claim 1 1 for treatment of the infection caused by resistant and non- resistant Mycobacterium tuberculosis as defined above by inhibition of GPR109A by an agent.
PCT/IN2015/000226 2014-05-30 2015-06-01 Novel compounds as anti-tubercular agents WO2015181837A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP15800492.9A EP3148518B1 (en) 2014-05-30 2015-06-01 Novel compounds as anti-tubercular agents
US15/313,986 US10100012B2 (en) 2014-05-30 2015-06-01 Compounds as anti-tubercular agents
CN201580041254.0A CN106659697B (en) 2014-05-30 2015-06-01 Compounds as antituberculosis agents
RU2016152499A RU2016152499A (en) 2014-05-30 2015-06-01 New compounds as anti-TB drugs
BR112016028081A BR112016028081A2 (en) 2014-05-30 2015-06-01 NEW COMPOUNDS AS ANTITUBERCULAR AGENTS
JP2017515286A JP6836502B2 (en) 2014-05-30 2015-06-01 New compound as an anti-tuberculosis drug
US15/674,033 US10207993B2 (en) 2014-05-30 2017-08-10 Compounds as anti-tubercular agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1431DE2014 2014-05-30
IN1431/DEL/2014 2014-05-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/313,986 A-371-Of-International US10100012B2 (en) 2014-05-30 2015-06-01 Compounds as anti-tubercular agents
US15/674,033 Division US10207993B2 (en) 2014-05-30 2017-08-10 Compounds as anti-tubercular agents

Publications (2)

Publication Number Publication Date
WO2015181837A2 true WO2015181837A2 (en) 2015-12-03
WO2015181837A3 WO2015181837A3 (en) 2016-02-18

Family

ID=54700005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000226 WO2015181837A2 (en) 2014-05-30 2015-06-01 Novel compounds as anti-tubercular agents

Country Status (7)

Country Link
US (2) US10100012B2 (en)
EP (1) EP3148518B1 (en)
JP (1) JP6836502B2 (en)
CN (1) CN106659697B (en)
BR (1) BR112016028081A2 (en)
RU (1) RU2016152499A (en)
WO (1) WO2015181837A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981720B (en) * 2019-12-24 2020-11-03 河南大学 Diaryl acetate compound and preparation method thereof
US20240002372A1 (en) * 2020-11-26 2024-01-04 Rezubio Pharmaceuticals Co., Ltd Anticholinergic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2955114A (en) 1958-03-12 1960-10-04 Lakeside Lab Inc Nor-piperidyl glycolate esters
US2995492A (en) 1957-12-23 1961-08-08 Lakeside Lab Inc Piperidine derivatives with psychotogenic activity
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844591A (en) * 1955-10-14 1958-07-22 Mead Johnson & Co 1-substituted-3-pyrrolidylmethyl benzilates and salts thereof
US2918408A (en) 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodic compositions specific for treating spasm of the colon
DE3614363A1 (en) * 1986-04-28 1987-10-29 Hoechst Ag BENZOTHIAZINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
US5750540A (en) * 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
JP3965442B2 (en) * 1995-06-26 2007-08-29 久光製薬株式会社 Substituted piperidine derivatives and pharmaceuticals containing the same
GB2340490A (en) * 1997-05-07 2000-02-23 Lovesgrove Res Ltd Diphenylacetic acid derivatives and their use as antiviral agents
JPH11193271A (en) * 1997-10-31 1999-07-21 Ss Pharmaceut Co Ltd Arylacetamide derivative or its salt and medicine containing the same
KR19990037220A (en) * 1997-10-31 1999-05-25 타이도 나오카타 Arylacetic acid amide derivatives or salts thereof and pharmaceuticals containing the same
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
AU5032400A (en) * 1999-05-21 2000-12-12 Wake Forest University Sigma-1 ligands useful for determining the proliferative status of cancer cells
CA2415468A1 (en) 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
ITMI20010395A1 (en) * 2001-02-27 2002-08-27 Dompe Spa OMEGA-AMINO ALKYLAMIDS OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF CHEMOTAXIS OF POLYMORPHONUCLEATED AND MONONUCLEATE CELLS
ITMI20012025A1 (en) * 2001-09-28 2003-03-28 Dompe Spa QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2204295B1 (en) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
WO2008073623A2 (en) * 2006-11-02 2008-06-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
ES2547415T3 (en) * 2009-02-27 2015-10-06 Raqualia Pharma Inc Oxyindole derivatives with motilin receptor agonist activity
WO2012020813A1 (en) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 Fused-ring pyrrolidine derivative
CN102144992B (en) * 2011-03-10 2013-04-10 浙江大学 Bacteriostatic and bactericidal activity of phenylglycine derivatives to Staphylococcus aureus
PT2685986T (en) * 2011-03-18 2020-03-05 Genzyme Corp Glucosylceramide synthase inhibitors
CN102516113B (en) * 2011-11-11 2014-04-09 四川大学 Series of diphenyl oxide derivatives and use of diphenyl oxide derivatives in preparation of anti-tuberculosis drugs
EP3082805B1 (en) * 2013-12-20 2020-02-05 Institute for Drug Discovery, LLC Substituted amino triazoles, and methods using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2995492A (en) 1957-12-23 1961-08-08 Lakeside Lab Inc Piperidine derivatives with psychotogenic activity
US2955114A (en) 1958-03-12 1960-10-04 Lakeside Lab Inc Nor-piperidyl glycolate esters
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3148518A4

Also Published As

Publication number Publication date
RU2016152499A (en) 2018-07-04
JP6836502B2 (en) 2021-03-03
CN106659697A (en) 2017-05-10
JP2017522366A (en) 2017-08-10
US20170183305A1 (en) 2017-06-29
EP3148518B1 (en) 2022-11-30
BR112016028081A2 (en) 2017-08-22
EP3148518A4 (en) 2017-05-17
WO2015181837A3 (en) 2016-02-18
CN106659697B (en) 2022-03-29
US20170334851A1 (en) 2017-11-23
EP3148518A2 (en) 2017-04-05
US10100012B2 (en) 2018-10-16
US10207993B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
CN110240596B (en) Therapeutic agents for the treatment of HBV infection
US9493440B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2019532995A (en) Tau protein targeted PROTAC and related methods of use
EP4056563A1 (en) Compound as shp2 inhibitor and use thereof
KR20190039591A (en) Pyrazolopyridine derivatives having GLP-1 receptor agonist action
KR102204804B1 (en) Dihydropyrazole gpr40 modulators
US9688654B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
TW201823249A (en) Fused bicyclic inhibitors of menin-mll interaction
WO2017129116A1 (en) Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
CN114867727A (en) TAU protein targeting compounds and related methods of use
CN114867720A (en) Heteroaryl derivative and preparation method and application thereof
NO20023750L (en) 1H-imidazopyridine
EP2763978B1 (en) Carbamate/ urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors
TW201835084A (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
US11498896B2 (en) Dopamine D2 receptor ligands
EP3083627B1 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
WO2004043936A1 (en) Plk inhibitors
JP2022511236A (en) Substituted quinazolinone derivative, and its use as a positive allosteric regulator of mGluR4
US10207993B2 (en) Compounds as anti-tubercular agents
US20220298135A1 (en) 5-heteroaryl-pyridin-2-amine compounds as neuropeptide ff receptor antagonists
US20230391776A1 (en) Amide oxazole compound
US20230390404A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
KR20240107333A (en) 15-PGDH inhibitors and uses
US20230406844A1 (en) N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800492

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15313986

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2017515286

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015800492

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016028081

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2015800492

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016152499

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016028081

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161129